

SUPPLEMENTARY MATERIALS

Safety, Tolerability, and Pharmacokinetics of Same-Knee Intra-Articular Injection of Corticosteroid and Lorecivint Within 7 Days: An Open-Label, Randomized, Parallel-Arm Study

Mark S. Fineman¹, Timothy E. McAlindon², Christian Lattermann³, Christopher J. Swearingen¹, Sarah Kennedy¹, Victor A. Lopez¹, Ismail Simsek¹, Jeyanesh R.S. Tambiah¹, Yusuf Yazici^{1,4}

1. Biosplice Therapeutics, Inc., 9360 Towne Center Dr., San Diego, CA 92121, USA
2. Tufts Medical Center, Boston, MA, USA
3. Brigham and Women's Hospital, Boston, MA, USA
4. NYU Grossman School of Medicine, New York, NY, USA

Corresponding author e-mail: Yusuf.Yazici@biosplice.com

Supplementary Material: Subject-level PK data listings

Samumed, LLC
Protocol: SM04690-OA-16

Page 1 of 80

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration

Individual Values: All Enrolled Subjects

Treatment Arm 1: TA + LOR

| Subject ID | Sex/ Age | Study Injection | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments | | |
|------------|----------|-----------------|------------|----------|-----------|------------------------------|------------|-------------|----------------------------------|----|--|
| | | | | Date | Time | | | | | | |
| 1003 | M/43 | TA | DAY 1 | PRE-DOSE | 21OCT2020 | 07:50 | -0.17 | <20.0 | NA | | |
| | | | | 1 H | 21OCT2020 | 09:00 | 1.00 | 6110 | NA | | |
| | | | | 2 H | 21OCT2020 | 10:00 | 2.00 | 8120 | NA | | |
| | | | | 4 H | 21OCT2020 | 12:00 | 4.00 | 9810 | NA | | |
| | | | | 6 H | 21OCT2020 | 14:00 | 6.00 | 8740 | NA | | |
| | | | | 8 H | 21OCT2020 | 16:00 | 8.00 | 6420 | NA | | |
| | | | | 10 H | 21OCT2020 | 18:00 | 10.00 | 4290 | NA | | |
| | | | | 12 H | 21OCT2020 | 20:00 | 12.00 | 3340 | NA | | |
| | | | | DAY 2 | 24 H | 22OCT2020 | 08:00 | 24.00 | 2440 | NA | |
| | | | | DAY 3 | 48 H | 23OCT2020 | 08:00 | 48.00 | 1480 | NA | |
| | | | | DAY 5 | 96 H | 25OCT2020 | 08:00 | 96.00 | 815 | NA | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetonide, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

PROGRAM PATH: Z:\~\QSC203941\~\TFLS\PRODUCTION\LIS-PC

09APR2021 10:11

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
Individual Values: All Enrolled Subjects
Treatment Arm 1: TA + LOR

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|--------|------------|-----------|-------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1003 | M/43 | LOR | DAY 8 | PRE-DOSE | 28OCT2020 | 07:55 | 167.92 | 461 | BQL | |
| | | | | 0.25 H | 28OCT2020 | 08:15 | 168.25 | NA | BQL | |
| | | | | 0.5 H | 28OCT2020 | 08:30 | 168.50 | NA | BQL | |
| | | | | 1 H | 28OCT2020 | 09:00 | 169.00 | 445 | BQL | |
| | | | | 2 H | 28OCT2020 | 10:00 | 170.00 | 364 | BQL | |
| | | | | 4 H | 28OCT2020 | 12:00 | 172.00 | 363 | BQL | |
| | | | | 6 H | 28OCT2020 | 14:00 | 174.00 | 308 | BQL | |
| | | | | 8 H | 28OCT2020 | 16:00 | 176.00 | 383 | BQL | |
| | | | DAY 11 | 72 H | 31OCT2020 | 08:00 | 240.00 | 335 | NA | |
| | | | DAY 15 | 168 H | 04NOV2020 | 08:00 | 336.00 | 192 | NA | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
 Individual Values: All Enrolled Subjects
 Treatment Arm 1: TA + LOR

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|-------|------------|-----------|-------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1004 | M/31 | TA | DAY 1 | PRE-DOSE | 21OCT2020 | 08:05 | -0.17 | <20.0 | NA | |
| | | | | 1 H | 21OCT2020 | 09:15 | 1.00 | 11900 | NA | |
| | | | | 2 H | 21OCT2020 | 10:15 | 2.00 | 19400 | NA | |
| | | | | 4 H | 21OCT2020 | 12:15 | 4.00 | 24700 | NA | |
| | | | | 6 H | 21OCT2020 | 14:15 | 6.00 | 27500 | NA | |
| | | | | 8 H | 21OCT2020 | 16:15 | 8.00 | 29500 | NA | |
| | | | | 10 H | 21OCT2020 | 18:15 | 10.00 | 24900 | NA | |
| | | | | 12 H | 21OCT2020 | 20:15 | 12.00 | 19500 | NA | |
| | | | | 24 H | 22OCT2020 | 08:15 | 24.00 | 20100 | NA | |
| | | | | 48 H | 23OCT2020 | 08:15 | 48.00 | 4230 | NA | |
| | | | | 96 H | 25OCT2020 | 08:15 | 96.00 | 629 | NA | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetonide, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
Individual Values: All Enrolled Subjects
Treatment Arm 1: TA + LOR

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|--------|------------|-----------|-------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1004 | M/31 | LOR | DAY 8 | PRE-DOSE | 28OCT2020 | 08:10 | 167.92 | 113 | BQL | |
| | | | | 0.25 H | 28OCT2020 | 08:30 | 168.25 | NA | BQL | |
| | | | | 0.5 H | 28OCT2020 | 08:45 | 168.50 | NA | BQL | |
| | | | | 1 H | 28OCT2020 | 09:15 | 169.00 | 99.4 | BQL | |
| | | | | 2 H | 28OCT2020 | 10:15 | 170.00 | 97.0 | BQL | |
| | | | | 4 H | 28OCT2020 | 12:15 | 172.00 | 100 | BQL | |
| | | | | 6 H | 28OCT2020 | 14:15 | 174.00 | 86.2 | BQL | |
| | | | | 8 H | 28OCT2020 | 16:15 | 176.00 | 89.5 | BQL | |
| | | | DAY 11 | 72 H | 31OCT2020 | 08:15 | 240.00 | 45.4 | NA | |
| | | | DAY 15 | 168 H | 04NOV2020 | 08:15 | 336.00 | <20.0 | NA | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
 Individual Values: All Enrolled Subjects
 Treatment Arm 1: TA + LOR

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments | |
|------------|----------|-----------------|-------|------------|-----------|-----------|------------------------------|------------|-------------|----------------------------------|--|
| | | | | | Date | Time | | | | | |
| 1006 | M/33 | TA | DAY 1 | PRE-DOSE | 21OCT2020 | 08:20 | -0.17 | <20.0 | NA | | |
| | | | | 1 H | 21OCT2020 | 09:30 | 1.00 | 1060 | NA | | |
| | | | | 2 H | 21OCT2020 | 10:30 | 2.00 | 793 | NA | | |
| | | | | 4 H | 21OCT2020 | 12:30 | 4.00 | 656 | NA | | |
| | | | | 6 H | 21OCT2020 | 14:30 | 6.00 | 550 | NA | | |
| | | | | 8 H | 21OCT2020 | 16:30 | 8.00 | 504 | NA | | |
| | | | | 10 H | 21OCT2020 | 18:30 | 10.00 | 449 | NA | | |
| | | | | 12 H | 21OCT2020 | 20:30 | 12.00 | 349 | NA | | |
| | | | | DAY 2 | 24 H | 22OCT2020 | 08:30 | 24.00 | 538 | NA | |
| | | | | DAY 3 | 48 H | 23OCT2020 | 08:30 | 48.00 | 434 | NA | |
| | | | | DAY 5 | 96 H | 25OCT2020 | 08:30 | 96.00 | 311 | NA | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
Individual Values: All Enrolled Subjects
Treatment Arm 1: TA + LOR

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|--------|------------|-----------|-------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1006 | M/33 | LOR | DAY 8 | PRE-DOSE | 28OCT2020 | 08:25 | 167.92 | 280 | BQL | |
| | | | | 0.25 H | 28OCT2020 | 08:45 | 168.25 | NA | BQL | |
| | | | | 0.5 H | 28OCT2020 | 09:00 | 168.50 | NA | BQL | |
| | | | | 1 H | 28OCT2020 | 09:30 | 169.00 | 208 | BQL | |
| | | | | 2 H | 28OCT2020 | 10:30 | 170.00 | 153 | BQL | |
| | | | | 4 H | 28OCT2020 | 12:30 | 172.00 | 103 | BQL | |
| | | | | 6 H | 28OCT2020 | 14:30 | 174.00 | 93.6 | BQL | |
| | | | | 8 H | 28OCT2020 | 16:30 | 176.00 | 142 | BQL | |
| | | | DAY 11 | 72 H | 31OCT2020 | 08:30 | 240.00 | 310 | NA | |
| | | | DAY 15 | 168 H | 04NOV2020 | 08:30 | 336.00 | 209 | NA | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
 Individual Values: All Enrolled Subjects
 Treatment Arm 1: TA + LOR

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments | |
|------------|----------|-----------------|-------|------------|-----------|-----------|------------------------------|------------|-------------|--|----|
| | | | | | Date | Time | | | | | |
| 1008 | F/54 | TA | DAY 1 | PRE-DOSE | 21OCT2020 | 08:35 | -0.17 | 41.1 | NA | Anomalous Result, confirmed by duplicate reassay | |
| | | | | 1 H | 21OCT2020 | 09:45 | 1.00 | 19200 | NA | | |
| | | | | 2 H | 21OCT2020 | 10:45 | 2.00 | 23500 | NA | | |
| | | | | 4 H | 21OCT2020 | 12:45 | 4.00 | 42300 | NA | | |
| | | | | 6 H | 21OCT2020 | 14:45 | 6.00 | 42800 | NA | | |
| | | | | 8 H | 21OCT2020 | 16:45 | 8.00 | 34200 | NA | | |
| | | | | 10 H | 21OCT2020 | 18:45 | 10.00 | 24600 | NA | | |
| | | | | 12 H | 21OCT2020 | 20:45 | 12.00 | 27100 | NA | | |
| | | | | DAY 2 | 24 H | 22OCT2020 | 08:45 | 24.00 | 18200 | | NA |
| | | | | DAY 3 | 48 H | 23OCT2020 | 08:45 | 48.00 | 7940 | | NA |
| | | | | DAY 5 | 96 H | 25OCT2020 | 08:45 | 96.00 | 1430 | | NA |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetonide, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit
 Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
 Individual Values: All Enrolled Subjects
 Treatment Arm 1: TA + LOR

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments | |
|------------|----------|-----------------|-------|------------|-----------|-----------|------------------------------|------------|-------------|----------------------------------|--|
| | | | | | Date | Time | | | | | |
| 1008 | F/54 | LOR | DAY 8 | PRE-DOSE | 28OCT2020 | 08:40 | 167.92 | 183 | BQL | | |
| | | | | 0.25 H | 28OCT2020 | 09:00 | 168.25 | NA | BQL | | |
| | | | | 0.5 H | 28OCT2020 | 09:15 | 168.50 | NA | BQL | | |
| | | | | 1 H | 28OCT2020 | 09:45 | 169.00 | 180 | BQL | | |
| | | | | 2 H | 28OCT2020 | 10:45 | 170.00 | 149 | BQL | | |
| | | | | 4 H | 28OCT2020 | 12:45 | 172.00 | 147 | BQL | | |
| | | | | 6 H | 28OCT2020 | 14:45 | 174.00 | 138 | BQL | | |
| | | | | 8 H | 28OCT2020 | 16:45 | 176.00 | 129 | BQL | | |
| | | | | DAY 11 | 72 H | 31OCT2020 | 08:45 | 240.00 | 86.8 | NA | |
| | | | | DAY 15 | 168 H | 04NOV2020 | 08:45 | 336.00 | 47.4 | NA | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
Individual Values: All Enrolled Subjects
Treatment Arm 1: TA + LOR

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|-------|------------|-----------|-------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1009 | F/46 | TA | DAY 1 | PRE-DOSE | 21OCT2020 | 08:50 | -0.17 | <20.0 | NA | |
| | | | | 1 H | 21OCT2020 | 10:00 | 1.00 | 11800 | NA | |
| | | | | 2 H | 21OCT2020 | 11:00 | 2.00 | 19600 | NA | |
| | | | | 4 H | 21OCT2020 | 13:00 | 4.00 | 27200 | NA | |
| | | | | 6 H | 21OCT2020 | 15:00 | 6.00 | 30500 | NA | |
| | | | | 8 H | 21OCT2020 | 17:00 | 8.00 | 44300 | NA | |
| | | | | 10 H | 21OCT2020 | 19:00 | 10.00 | 30700 | NA | |
| | | | | 12 H | 21OCT2020 | 21:00 | 12.00 | 29900 | NA | |
| | | | | 24 H | 22OCT2020 | 09:01 | 24.02 | 29100 | NA | |
| | | | | 48 H | 23OCT2020 | 09:00 | 48.00 | 6410 | NA | |
| | | | | 96 H | 25OCT2020 | 09:00 | 96.00 | 370 | NA | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
Individual Values: All Enrolled Subjects
Treatment Arm 1: TA + LOR

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|--------|------------|-----------|-------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1009 | F/46 | LOR | DAY 8 | PRE-DOSE | 28OCT2020 | 08:55 | 167.92 | 58.8 | BQL | |
| | | | | 0.25 H | 28OCT2020 | 09:15 | 168.25 | NA | BQL | |
| | | | | 0.5 H | 28OCT2020 | 09:30 | 168.50 | NA | BQL | |
| | | | | 1 H | 28OCT2020 | 10:00 | 169.00 | 59.6 | BQL | |
| | | | | 2 H | 28OCT2020 | 11:00 | 170.00 | 50.0 | BQL | |
| | | | | 4 H | 28OCT2020 | 13:00 | 172.00 | 48.9 | BQL | |
| | | | | 6 H | 28OCT2020 | 15:00 | 174.00 | 47.9 | BQL | |
| | | | | 8 H | 28OCT2020 | 17:00 | 176.00 | 58.2 | BQL | |
| | | | DAY 11 | 72 H | 31OCT2020 | 09:00 | 240.00 | 31.2 | NA | |
| | | | DAY 15 | 168 H | 04NOV2020 | 09:00 | 336.00 | <20.0 | NA | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
 Individual Values: All Enrolled Subjects
 Treatment Arm 1: TA + LOR

| Subject ID | Sex/ Age | Study Injection | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments | |
|------------|----------|-----------------|------------|-----------|-----------|------------------------------|------------|-------------|----------------------------------|--|
| | | | | Date | Time | | | | | |
| 1010 | F/48 TA | DAY 1 | PRE-DOSE | 21OCT2020 | 09:05 | -0.17 | <20.0 | NA | | |
| | | | 1 H | 21OCT2020 | 10:15 | 1.00 | 8400 | NA | | |
| | | | 2 H | 21OCT2020 | 11:15 | 2.00 | 12600 | NA | | |
| | | | 4 H | 21OCT2020 | 13:15 | 4.00 | 25600 | NA | | |
| | | | 6 H | 21OCT2020 | 15:15 | 6.00 | 29600 | NA | | |
| | | | 8 H | 21OCT2020 | 17:15 | 8.00 | 36700 | NA | | |
| | | | 10 H | 21OCT2020 | 19:15 | 10.00 | 26600 | NA | | |
| | | | 12 H | 21OCT2020 | 21:15 | 12.00 | 23200 | NA | | |
| | | | DAY 2 | 24 H | 22OCT2020 | 09:15 | 24.00 | 15100 | NA | |
| | | | DAY 3 | 48 H | 23OCT2020 | 09:15 | 48.00 | 6160 | NA | |
| | | | DAY 5 | 96 H | 25OCT2020 | 09:15 | 96.00 | 749 | NA | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
 Individual Values: All Enrolled Subjects
 Treatment Arm 1: TA + LOR

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|--------|------------|-----------|-------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1010 | F/48 | LOR | DAY 8 | PRE-DOSE | 28OCT2020 | 09:10 | 167.92 | 61.7 | BQL | |
| | | | | 0.25 H | 28OCT2020 | 09:30 | 168.25 | NA | BQL | |
| | | | | 0.5 H | 28OCT2020 | 09:45 | 168.50 | NA | BQL | |
| | | | | 1 H | 28OCT2020 | 10:15 | 169.00 | 56.1 | BQL | |
| | | | | 2 H | 28OCT2020 | 11:15 | 170.00 | 53.3 | BQL | |
| | | | | 4 H | 28OCT2020 | 13:15 | 172.00 | 49.3 | BQL | |
| | | | | 6 H | 28OCT2020 | 15:15 | 174.00 | 44.3 | BQL | |
| | | | | 8 H | 28OCT2020 | 17:15 | 176.00 | 40.2 | BQL | |
| | | | DAY 11 | 72 H | 31OCT2020 | 09:15 | 240.00 | <20.0 | NA | |
| | | | DAY 15 | 168 H | 04NOV2020 | 09:15 | 336.00 | <20.0 | NA | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
 Individual Values: All Enrolled Subjects
 Treatment Arm 1: TA + LOR

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|-------|------------|-----------|-------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1014 | M/46 | TA | DAY 1 | PRE-DOSE | 05NOV2020 | 07:50 | -0.17 | <20.0 | NA | |
| | | | | 1 H | 05NOV2020 | 09:00 | 1.00 | 147 | NA | |
| | | | | 2 H | 05NOV2020 | 10:00 | 2.00 | 160 | NA | |
| | | | | 4 H | 05NOV2020 | 12:00 | 4.00 | 128 | NA | |
| | | | | 6 H | 05NOV2020 | 14:00 | 6.00 | 139 | NA | |
| | | | | 8 H | 05NOV2020 | 16:00 | 8.00 | 140 | NA | |
| | | | | 10 H | 05NOV2020 | 18:00 | 10.00 | 158 | NA | |
| | | | | 12 H | 05NOV2020 | 20:00 | 12.00 | 231 | NA | |
| | | | | DAY 2 | 06NOV2020 | 08:00 | 24.00 | 294 | NA | |
| | | | | DAY 3 | 07NOV2020 | 08:00 | 48.00 | 323 | NA | |
| | | | | DAY 5 | 09NOV2020 | 08:00 | 96.00 | 286 | NA | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
Individual Values: All Enrolled Subjects
Treatment Arm 1: TA + LOR

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|--------|------------|-----------|-------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1014 | M/46 | LOR | DAY 8 | PRE-DOSE | 12NOV2020 | 07:55 | 167.92 | 303 | BQL | |
| | | | | 0.25 H | 12NOV2020 | 08:15 | 168.25 | NA | BQL | |
| | | | | 0.5 H | 12NOV2020 | 08:30 | 168.50 | NA | BQL | |
| | | | | 1 H | 12NOV2020 | 09:00 | 169.00 | 309 | BQL | |
| | | | | 2 H | 12NOV2020 | 10:00 | 170.00 | 231 | BQL | |
| | | | | 4 H | 12NOV2020 | 12:00 | 172.00 | 212 | BQL | |
| | | | | 6 H | 12NOV2020 | 14:00 | 174.00 | 181 | BQL | |
| | | | | 8 H | 12NOV2020 | 16:00 | 176.00 | 200 | BQL | |
| | | | DAY 11 | 72 H | 15NOV2020 | 08:00 | 240.00 | 370 | NA | |
| | | | DAY 15 | 168 H | 19NOV2020 | 08:00 | 336.00 | 374 | NA | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
 Individual Values: All Enrolled Subjects
 Treatment Arm 1: TA + LOR

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|-------|------------|-----------|-------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1015 | M/31 | TA | DAY 1 | PRE-DOSE | 05NOV2020 | 08:02 | -0.17 | <20.0 | NA | |
| | | | | 1 H | 05NOV2020 | 09:12 | 1.00 | 3790 | NA | |
| | | | | 2 H | 05NOV2020 | 10:12 | 2.00 | 6570 | NA | |
| | | | | 4 H | 05NOV2020 | 12:12 | 4.00 | 10400 | NA | |
| | | | | 6 H | 05NOV2020 | 14:12 | 6.00 | 11500 | NA | |
| | | | | 8 H | 05NOV2020 | 16:12 | 8.00 | 11100 | NA | |
| | | | | 10 H | 05NOV2020 | 18:12 | 10.00 | 7180 | NA | |
| | | | | 12 H | 05NOV2020 | 20:12 | 12.00 | 5730 | NA | |
| | | | | DAY 2 | 06NOV2020 | 08:12 | 24.00 | 2630 | NA | |
| | | | | DAY 3 | 07NOV2020 | 08:12 | 48.00 | 690 | NA | |
| | | | | DAY 5 | 09NOV2020 | 08:12 | 96.00 | 438 | NA | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit
 Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
 Individual Values: All Enrolled Subjects
 Treatment Arm 1: TA + LOR

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments | |
|------------|----------|-----------------|-------|------------|-----------|-----------|------------------------------|------------|-------------|----------------------------------|--|
| | | | | | Date | Time | | | | | |
| 1015 | M/31 | LOR | DAY 8 | PRE-DOSE | 12NOV2020 | 08:07 | 167.92 | 367 | BQL | | |
| | | | | 0.25 H | 12NOV2020 | 08:27 | 168.25 | NA | BQL | | |
| | | | | 0.5 H | 12NOV2020 | 08:42 | 168.50 | NA | BQL | | |
| | | | | 1 H | 12NOV2020 | 09:12 | 169.00 | 315 | BQL | | |
| | | | | 2 H | 12NOV2020 | 10:12 | 170.00 | 305 | BQL | | |
| | | | | 4 H | 12NOV2020 | 12:12 | 172.00 | 248 | BQL | | |
| | | | | 6 H | 12NOV2020 | 14:12 | 174.00 | 201 | BQL | | |
| | | | | 8 H | 12NOV2020 | 16:12 | 176.00 | 199 | BQL | | |
| | | | | DAY 11 | 72 H | 15NOV2020 | 08:12 | 240.00 | 453 | NA | |
| | | | | DAY 15 | 168 H | 19NOV2020 | 08:12 | 336.00 | 444 | NA | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
Individual Values: All Enrolled Subjects
Treatment Arm 1: TA + LOR

| Subject ID | Sex/ Age | Study Injection | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments | |
|------------|----------|-----------------|------------|----------|-----------|------------------------------|------------|-------------|----------------------------------|----|
| | | | | Date | Time | | | | | |
| 1017 | M/40 | TA | DAY 1 | PRE-DOSE | 05NOV2020 | 08:14 | -0.17 | <20.0 | NA | |
| | | | | 1 H | 05NOV2020 | 09:24 | 1.00 | 274 | NA | |
| | | | | 2 H | 05NOV2020 | 10:24 | 2.00 | 385 | NA | |
| | | | | 4 H | 05NOV2020 | 12:24 | 4.00 | 490 | NA | |
| | | | | 6 H | 05NOV2020 | 14:24 | 6.00 | 617 | NA | |
| | | | | 8 H | 05NOV2020 | 16:24 | 8.00 | 866 | NA | |
| | | | | 10 H | 05NOV2020 | 18:24 | 10.00 | 831 | NA | |
| | | | | 12 H | 05NOV2020 | 20:24 | 12.00 | 883 | NA | |
| | | | | DAY 2 | 24 H | 06NOV2020 | 08:24 | 24.00 | 1320 | NA |
| | | | | DAY 3 | 48 H | 07NOV2020 | 08:24 | 48.00 | 1180 | NA |
| | | | | DAY 5 | 96 H | 09NOV2020 | 08:24 | 96.00 | 799 | NA |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
Individual Values: All Enrolled Subjects
Treatment Arm 1: TA + LOR

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|--------|------------|-----------|-------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1017 | M/40 | LOR | DAY 8 | PRE-DOSE | 12NOV2020 | 08:19 | 167.92 | 514 | BQL | |
| | | | | 0.25 H | 12NOV2020 | 08:39 | 168.25 | NA | BQL | |
| | | | | 0.5 H | 12NOV2020 | 08:54 | 168.50 | NA | BQL | |
| | | | | 1 H | 12NOV2020 | 09:24 | 169.00 | 692 | BQL | |
| | | | | 2 H | 12NOV2020 | 10:24 | 170.00 | 854 | BQL | |
| | | | | 4 H | 12NOV2020 | 12:24 | 172.00 | 892 | BQL | |
| | | | | 6 H | 12NOV2020 | 14:24 | 174.00 | 793 | BQL | |
| | | | | 8 H | 12NOV2020 | 16:24 | 176.00 | 989 | BQL | |
| | | | DAY 11 | 72 H | 15NOV2020 | 08:24 | 240.00 | 1010 | NA | |
| | | | DAY 15 | 168 H | 19NOV2020 | 08:24 | 336.00 | 833 | NA | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
 Individual Values: All Enrolled Subjects
 Treatment Arm 1: TA + LOR

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|-------|------------|-----------|-------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1018 | F/52 | TA | DAY 1 | PRE-DOSE | 05NOV2020 | 08:26 | -0.17 | <20.0 | NA | |
| | | | | 1 H | 05NOV2020 | 09:36 | 1.00 | 1750 | NA | |
| | | | | 2 H | 05NOV2020 | 10:36 | 2.00 | 2530 | NA | |
| | | | | 4 H | 05NOV2020 | 12:36 | 4.00 | 3140 | NA | |
| | | | | 6 H | 05NOV2020 | 14:36 | 6.00 | 5350 | NA | |
| | | | | 8 H | 05NOV2020 | 16:36 | 8.00 | 6850 | NA | |
| | | | | 10 H | 05NOV2020 | 18:36 | 10.00 | 4840 | NA | |
| | | | | 12 H | 05NOV2020 | 20:36 | 12.00 | 4670 | NA | |
| | | | | DAY 2 | 06NOV2020 | 08:36 | 24.00 | 2810 | NA | |
| | | | | DAY 3 | 07NOV2020 | 08:36 | 48.00 | 1220 | NA | |
| | | | | DAY 5 | 09NOV2020 | 08:36 | 96.00 | 633 | NA | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetonide, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit
 Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
Individual Values: All Enrolled Subjects
Treatment Arm 1: TA + LOR

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|--------|------------|-----------|-------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1018 | F/52 | LOR | DAY 8 | PRE-DOSE | 12NOV2020 | 08:31 | 167.92 | 486 | BQL | |
| | | | | 0.25 H | 12NOV2020 | 08:51 | 168.25 | NA | BQL | |
| | | | | 0.5 H | 12NOV2020 | 09:06 | 168.50 | NA | BQL | |
| | | | | 1 H | 12NOV2020 | 09:36 | 169.00 | 414 | BQL | |
| | | | | 2 H | 12NOV2020 | 10:36 | 170.00 | 361 | BQL | |
| | | | | 4 H | 12NOV2020 | 12:36 | 172.00 | 307 | BQL | |
| | | | | 6 H | 12NOV2020 | 14:36 | 174.00 | 285 | BQL | |
| | | | | 8 H | 12NOV2020 | 16:36 | 176.00 | 376 | BQL | |
| | | | DAY 11 | 72 H | 15NOV2020 | 08:36 | 240.00 | 467 | NA | |
| | | | DAY 15 | 168 H | 19NOV2020 | 08:36 | 336.00 | 338 | NA | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
 Individual Values: All Enrolled Subjects
 Treatment Arm 1: TA + LOR

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|-------|------------|-----------|-------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1022 | F/42 | TA | DAY 1 | PRE-DOSE | 05NOV2020 | 08:38 | -0.17 | <20.0 | NA | |
| | | | | 1 H | 05NOV2020 | 09:48 | 1.00 | 2160 | NA | |
| | | | | 2 H | 05NOV2020 | 10:48 | 2.00 | 2580 | NA | |
| | | | | 4 H | 05NOV2020 | 12:48 | 4.00 | 3130 | NA | |
| | | | | 6 H | 05NOV2020 | 14:48 | 6.00 | 2410 | NA | |
| | | | | 8 H | 05NOV2020 | 16:48 | 8.00 | 2330 | NA | |
| | | | | 10 H | 05NOV2020 | 18:48 | 10.00 | 1820 | NA | |
| | | | | 12 H | 05NOV2020 | 20:48 | 12.00 | 1410 | NA | |
| | | | | DAY 2 | 06NOV2020 | 08:48 | 24.00 | 1140 | NA | |
| | | | | DAY 3 | 07NOV2020 | 08:48 | 48.00 | 755 | NA | |
| | | | | DAY 5 | 09NOV2020 | 08:48 | 96.00 | 510 | NA | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetate, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit
 Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
Individual Values: All Enrolled Subjects
Treatment Arm 1: TA + LOR

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual | TA (pg/mL) | LOR (ng/mL) | TA and LOR |
|------------|----------|-----------------|--------|------------|-----------|-------|-----------------------|------------|-------------|-----------------------|
| | | | | | Date | Time | Time from TA Dose (h) | | | Any Relevant Comments |
| 1022 | F/42 | LOR | DAY 8 | PRE-DOSE | 12NOV2020 | 08:43 | 167.92 | 419 | BQL | |
| | | | | 0.25 H | 12NOV2020 | 09:03 | 168.25 | NA | BQL | |
| | | | | 0.5 H | 12NOV2020 | 09:18 | 168.50 | NA | BQL | |
| | | | | 1 H | 12NOV2020 | 09:48 | 169.00 | 310 | BQL | |
| | | | | 2 H | 12NOV2020 | 10:48 | 170.00 | 236 | BQL | |
| | | | | 4 H | 12NOV2020 | 12:48 | 172.00 | 192 | BQL | |
| | | | | 6 H | 12NOV2020 | 14:48 | 174.00 | 154 | BQL | |
| | | | | 8 H | 12NOV2020 | 16:48 | 176.00 | 258 | BQL | |
| | | | DAY 11 | 72 H | 15NOV2020 | 08:48 | 240.00 | 257 | NA | |
| | | | DAY 15 | 168 H | 19NOV2020 | 08:48 | 336.00 | 298 | NA | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
 Individual Values: All Enrolled Subjects
 Treatment Arm 1: TA + LOR

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|-------|------------|-----------|-------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1023 | M/38 | TA | DAY 1 | PRE-DOSE | 18NOV2020 | 07:50 | -0.15 | <20.0 | NA | |
| | | | | 1 H | 18NOV2020 | 08:59 | 1.00 | 7120 | NA | |
| | | | | 2 H | 18NOV2020 | 09:59 | 2.00 | 10200 | NA | |
| | | | | 4 H | 18NOV2020 | 11:59 | 4.00 | 14000 | NA | |
| | | | | 6 H | 18NOV2020 | 13:59 | 6.00 | 20400 | NA | |
| | | | | 8 H | 18NOV2020 | 15:59 | 8.00 | 21400 | NA | |
| | | | | 10 H | 18NOV2020 | 17:59 | 10.00 | 14200 | NA | |
| | | | | 12 H | 18NOV2020 | 19:59 | 12.00 | 12100 | NA | |
| | | | | 24 H | 19NOV2020 | 07:59 | 24.00 | 9220 | NA | |
| | | | | 48 H | 20NOV2020 | 07:59 | 48.00 | 4840 | NA | |
| | | | | 96 H | 22NOV2020 | 07:59 | 96.00 | 2150 | NA | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit
 Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
 Individual Values: All Enrolled Subjects
 Treatment Arm 1: TA + LOR

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments | |
|------------|----------|-----------------|-------|------------|-----------|-----------|------------------------------|------------|-------------|----------------------------------|--|
| | | | | | Date | Time | | | | | |
| 1023 | M/38 | LOR | DAY 8 | PRE-DOSE | 25NOV2020 | 07:54 | 167.92 | 753 | BQL | | |
| | | | | 0.25 H | 25NOV2020 | 08:14 | 168.25 | NA | BQL | | |
| | | | | 0.5 H | 25NOV2020 | 08:29 | 168.50 | NA | BQL | | |
| | | | | 1 H | 25NOV2020 | 08:59 | 169.00 | 833 | BQL | | |
| | | | | 2 H | 25NOV2020 | 09:59 | 170.00 | 731 | BQL | | |
| | | | | 4 H | 25NOV2020 | 11:59 | 172.00 | 644 | BQL | | |
| | | | | 6 H | 25NOV2020 | 13:59 | 174.00 | 814 | BQL | | |
| | | | | 8 H | 25NOV2020 | 15:59 | 176.00 | 1080 | BQL | | |
| | | | | DAY 11 | 72 H | 28NOV2020 | 07:59 | 240.00 | 703 | NA | |
| | | | | DAY 15 | 168 H | 02DEC2020 | 07:59 | 336.00 | 320 | NA | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
 Individual Values: All Enrolled Subjects
 Treatment Arm 1: TA + LOR

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|-------|------------|-----------|-------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1026 | F/45 | TA | DAY 1 | PRE-DOSE | 18NOV2020 | 08:26 | -0.17 | <20.0 | NA | |
| | | | | 1 H | 18NOV2020 | 09:36 | 1.00 | 21400 | NA | |
| | | | | 2 H | 18NOV2020 | 10:36 | 2.00 | 33000 | NA | |
| | | | | 4 H | 18NOV2020 | 12:36 | 4.00 | 43300 | NA | |
| | | | | 6 H | 18NOV2020 | 14:36 | 6.00 | 40500 | NA | |
| | | | | 8 H | 18NOV2020 | 16:36 | 8.00 | 33900 | NA | |
| | | | | 10 H | 18NOV2020 | 18:36 | 10.00 | 26400 | NA | |
| | | | | 12 H | 18NOV2020 | 20:36 | 12.00 | 24700 | NA | |
| | | | | 24 H | 19NOV2020 | 08:36 | 24.00 | 20100 | NA | |
| | | | | 48 H | 20NOV2020 | 08:36 | 48.00 | 4830 | NA | |
| | | | | 96 H | 22NOV2020 | 08:36 | 96.00 | 544 | NA | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
 Individual Values: All Enrolled Subjects
 Treatment Arm 1: TA + LOR

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|--------|------------|-----------|-------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1026 | F/45 | LOR | DAY 8 | PRE-DOSE | 25NOV2020 | 08:31 | 167.92 | 55.4 | BQL | |
| | | | | 0.25 H | 25NOV2020 | 08:51 | 168.25 | NA | BQL | |
| | | | | 0.5 H | 25NOV2020 | 09:06 | 168.50 | NA | BQL | |
| | | | | 1 H | 25NOV2020 | 09:36 | 169.00 | 53.0 | BQL | |
| | | | | 2 H | 25NOV2020 | 10:36 | 170.00 | 43.6 | BQL | |
| | | | | 4 H | 25NOV2020 | 12:36 | 172.00 | 37.5 | BQL | |
| | | | | 6 H | 25NOV2020 | 14:36 | 174.00 | 34.3 | BQL | |
| | | | | 8 H | 25NOV2020 | 16:36 | 176.00 | 37.8 | BQL | |
| | | | DAY 11 | 72 H | 28NOV2020 | 08:36 | 240.00 | <20.0 | NA | |
| | | | DAY 15 | 168 H | 02DEC2020 | 08:36 | 336.00 | <20.0 | NA | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
 Individual Values: All Enrolled Subjects
 Treatment Arm 1: TA + LOR

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|-------|------------|-----------|-------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1027 | F/40 | TA | DAY 1 | PRE-DOSE | 18NOV2020 | 08:38 | -0.17 | <20.0 | NA | |
| | | | | 1 H | 18NOV2020 | 09:48 | 1.00 | 6910 | NA | |
| | | | | 2 H | 18NOV2020 | 10:48 | 2.00 | 7710 | NA | |
| | | | | 4 H | 18NOV2020 | 12:48 | 4.00 | 9720 | NA | |
| | | | | 6 H | 18NOV2020 | 14:48 | 6.00 | 15100 | NA | |
| | | | | 8 H | 18NOV2020 | 16:48 | 8.00 | 16100 | NA | |
| | | | | 10 H | 18NOV2020 | 18:48 | 10.00 | 14900 | NA | |
| | | | | 12 H | 18NOV2020 | 20:48 | 12.00 | 18300 | NA | |
| | | | | DAY 2 | 19NOV2020 | 08:48 | 24.00 | 12200 | NA | |
| | | | | DAY 3 | 20NOV2020 | 08:48 | 48.00 | 4190 | NA | |
| | | | | DAY 5 | 22NOV2020 | 08:48 | 96.00 | 1040 | NA | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit
 Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
Individual Values: All Enrolled Subjects
Treatment Arm 1: TA + LOR

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|--------|------------|-----------|-------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1027 | F/40 | LOR | DAY 8 | PRE-DOSE | 25NOV2020 | 08:43 | 167.92 | 231 | BQL | |
| | | | | 0.25 H | 25NOV2020 | 09:03 | 168.25 | NA | BQL | |
| | | | | 0.5 H | 25NOV2020 | 09:18 | 168.50 | NA | BQL | |
| | | | | 1 H | 25NOV2020 | 09:48 | 169.00 | 176 | BQL | |
| | | | | 2 H | 25NOV2020 | 10:48 | 170.00 | 138 | BQL | |
| | | | | 4 H | 25NOV2020 | 12:48 | 172.00 | 111 | BQL | |
| | | | | 6 H | 25NOV2020 | 14:48 | 174.00 | 86.5 | BQL | |
| | | | | 8 H | 25NOV2020 | 16:48 | 176.00 | 87.0 | BQL | |
| | | | DAY 11 | 72 H | 28NOV2020 | 08:48 | 240.00 | 173 | NA | |
| | | | DAY 15 | 168 H | 02DEC2020 | 08:48 | 336.00 | 124 | NA | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
 Individual Values: All Enrolled Subjects
 Treatment Arm 1: TA + LOR

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|-------|------------|-----------|-------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1031 | M/51 | TA | DAY 1 | PRE-DOSE | 18NOV2020 | 08:02 | -0.17 | <20.0 | NA | |
| | | | | 1 H | 18NOV2020 | 09:12 | 1.00 | 1330 | NA | |
| | | | | 2 H | 18NOV2020 | 10:12 | 2.00 | 2240 | NA | |
| | | | | 4 H | 18NOV2020 | 12:12 | 4.00 | 3750 | NA | |
| | | | | 6 H | 18NOV2020 | 14:12 | 6.00 | 4260 | NA | |
| | | | | 8 H | 18NOV2020 | 16:12 | 8.00 | 5060 | NA | |
| | | | | 10 H | 18NOV2020 | 18:12 | 10.00 | 4210 | NA | |
| | | | | 12 H | 18NOV2020 | 20:12 | 12.00 | 4160 | NA | |
| | | | | DAY 2 | 19NOV2020 | 08:12 | 24.00 | 1730 | NA | |
| | | | | DAY 3 | 20NOV2020 | 08:12 | 48.00 | 626 | NA | |
| | | | | DAY 5 | 22NOV2020 | 08:12 | 96.00 | 292 | NA | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
 Individual Values: All Enrolled Subjects
 Treatment Arm 1: TA + LOR

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments | |
|------------|----------|-----------------|-------|------------|-----------|-----------|------------------------------|------------|-------------|----------------------------------|--|
| | | | | | Date | Time | | | | | |
| 1031 | M/51 | LOR | DAY 8 | PRE-DOSE | 25NOV2020 | 08:07 | 167.92 | 242 | BQL | | |
| | | | | 0.25 H | 25NOV2020 | 08:27 | 168.25 | NA | BQL | | |
| | | | | 0.5 H | 25NOV2020 | 08:42 | 168.50 | NA | BQL | | |
| | | | | 1 H | 25NOV2020 | 09:12 | 169.00 | 266 | BQL | | |
| | | | | 2 H | 25NOV2020 | 10:12 | 170.00 | 237 | BQL | | |
| | | | | 4 H | 25NOV2020 | 12:12 | 172.00 | 234 | BQL | | |
| | | | | 6 H | 25NOV2020 | 14:12 | 174.00 | 126 | BQL | | |
| | | | | 8 H | 25NOV2020 | 16:12 | 176.00 | 203 | BQL | | |
| | | | | DAY 11 | 72 H | 28NOV2020 | 08:12 | 240.00 | 276 | NA | |
| | | | | DAY 15 | 168 H | 02DEC2020 | 08:12 | 336.00 | 247 | NA | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
 Individual Values: All Enrolled Subjects
 Treatment Arm 1: TA + LOR

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|-------|------------|-----------|-------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1032 | M/40 | TA | DAY 1 | PRE-DOSE | 18NOV2020 | 08:14 | -0.17 | <20.0 | NA | |
| | | | | 1 H | 18NOV2020 | 09:24 | 1.00 | 295 | NA | |
| | | | | 2 H | 18NOV2020 | 10:24 | 2.00 | 315 | NA | |
| | | | | 4 H | 18NOV2020 | 12:24 | 4.00 | 364 | NA | |
| | | | | 6 H | 18NOV2020 | 14:24 | 6.00 | 385 | NA | |
| | | | | 8 H | 18NOV2020 | 16:24 | 8.00 | 428 | NA | |
| | | | | 10 H | 18NOV2020 | 18:24 | 10.00 | 430 | NA | |
| | | | | 12 H | 18NOV2020 | 20:24 | 12.00 | 759 | NA | |
| | | | | DAY 2 | 19NOV2020 | 08:24 | 24.00 | 929 | NA | |
| | | | | DAY 3 | 20NOV2020 | 08:24 | 48.00 | 666 | NA | |
| | | | | DAY 5 | 22NOV2020 | 08:24 | 96.00 | 239 | NA | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
 Individual Values: All Enrolled Subjects
 Treatment Arm 1: TA + LOR

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments | |
|------------|----------|-----------------|-------|------------|-----------|-----------|------------------------------|------------|-------------|----------------------------------|--|
| | | | | | Date | Time | | | | | |
| 1032 | M/40 | LOR | DAY 8 | PRE-DOSE | 25NOV2020 | 08:19 | 167.92 | 337 | BQL | | |
| | | | | 0.25 H | 25NOV2020 | 08:39 | 168.25 | NA | BQL | | |
| | | | | 0.5 H | 25NOV2020 | 08:54 | 168.50 | NA | BQL | | |
| | | | | 1 H | 25NOV2020 | 09:24 | 169.00 | 310 | BQL | | |
| | | | | 2 H | 25NOV2020 | 10:24 | 170.00 | 251 | BQL | | |
| | | | | 4 H | 25NOV2020 | 12:24 | 172.00 | 260 | BQL | | |
| | | | | 6 H | 25NOV2020 | 14:24 | 174.00 | 205 | BQL | | |
| | | | | 8 H | 25NOV2020 | 16:24 | 176.00 | 279 | BQL | | |
| | | | | DAY 11 | 72 H | 28NOV2020 | 08:24 | 240.00 | 428 | NA | |
| | | | | DAY 15 | 168 H | 02DEC2020 | 08:24 | 336.00 | 362 | NA | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
 Individual Values: All Enrolled Subjects
 Treatment Arm 1: TA + LOR

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments | |
|------------|----------|-----------------|-------|------------|-----------|-----------|------------------------------|------------|-------------|----------------------------------|--|
| | | | | | Date | Time | | | | | |
| 1033 | M/31 | TA | DAY 1 | PRE-DOSE | 01DEC2020 | 07:50 | -0.17 | <20.0 | NA | | |
| | | | | 1 H | 01DEC2020 | 09:00 | 1.00 | 302 | NA | | |
| | | | | 2 H | 01DEC2020 | 10:00 | 2.00 | 315 | NA | | |
| | | | | 4 H | 01DEC2020 | 12:00 | 4.00 | 300 | NA | | |
| | | | | 6 H | 01DEC2020 | 14:00 | 6.00 | 314 | NA | | |
| | | | | 8 H | 01DEC2020 | 16:00 | 8.00 | 256 | NA | | |
| | | | | 10 H | 01DEC2020 | 18:00 | 10.00 | 251 | NA | | |
| | | | | 12 H | 01DEC2020 | 20:00 | 12.00 | 263 | NA | | |
| | | | | DAY 2 | 24 H | 02DEC2020 | 08:00 | 24.00 | 963 | NA | |
| | | | | DAY 3 | 48 H | 03DEC2020 | 08:00 | 48.00 | 909 | NA | |
| | | | | DAY 5 | 96 H | 05DEC2020 | 08:00 | 96.00 | 209 | NA | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
Individual Values: All Enrolled Subjects
Treatment Arm 1: TA + LOR

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual | | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|--------|------------|-----------|-------|-----------------------|-----|------------|-------------|----------------------------------|
| | | | | | Date | Time | Time from TA Dose (h) | | | | |
| 1033 | M/31 | LOR | DAY 8 | PRE-DOSE | 08DEC2020 | 07:55 | 167.92 | 691 | BQL | | |
| | | | | 0.25 H | 08DEC2020 | 08:15 | 168.25 | NA | BQL | | |
| | | | | 0.5 H | 08DEC2020 | 08:30 | 168.50 | NA | BQL | | |
| | | | | 1 H | 08DEC2020 | 09:00 | 169.00 | 616 | BQL | | |
| | | | | 2 H | 08DEC2020 | 10:00 | 170.00 | 455 | BQL | | |
| | | | | 4 H | 08DEC2020 | 12:00 | 172.00 | 250 | BQL | | |
| | | | | 6 H | 08DEC2020 | 14:00 | 174.00 | 245 | BQL | | |
| | | | | 8 H | 08DEC2020 | 16:00 | 176.00 | 183 | BQL | | |
| | | | DAY 11 | 72 H | 11DEC2020 | 08:00 | 240.00 | 612 | NA | | |
| | | | DAY 15 | 168 H | 15DEC2020 | 08:00 | 336.00 | 495 | NA | | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
 Individual Values: All Enrolled Subjects
 Treatment Arm 1: TA + LOR

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|-------|------------|-----------|-------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1036 | M/37 | TA | DAY 1 | PRE-DOSE | 01DEC2020 | 08:02 | -0.17 | <20.0 | NA | |
| | | | | 1 H | 01DEC2020 | 09:12 | 1.00 | 197 | NA | |
| | | | | 2 H | 01DEC2020 | 10:12 | 2.00 | 331 | NA | |
| | | | | 4 H | 01DEC2020 | 12:12 | 4.00 | 378 | NA | |
| | | | | 6 H | 01DEC2020 | 14:12 | 6.00 | 290 | NA | |
| | | | | 8 H | 01DEC2020 | 16:12 | 8.00 | 278 | NA | |
| | | | | 10 H | 01DEC2020 | 18:12 | 10.00 | 293 | NA | |
| | | | | 12 H | 01DEC2020 | 20:12 | 12.00 | 388 | NA | |
| | | | | DAY 2 | 02DEC2020 | 08:12 | 24.00 | 839 | NA | |
| | | | | DAY 3 | 03DEC2020 | 08:12 | 48.00 | 683 | NA | |
| | | | | DAY 5 | 05DEC2020 | 08:12 | 96.00 | 178 | NA | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
Individual Values: All Enrolled Subjects
Treatment Arm 1: TA + LOR

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|--------|------------|-----------|-------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1036 | M/37 | LOR | DAY 8 | PRE-DOSE | 08DEC2020 | 08:07 | 167.92 | 357 | BQL | |
| | | | | 0.25 H | 08DEC2020 | 08:27 | 168.25 | NA | BQL | |
| | | | | 0.5 H | 08DEC2020 | 08:42 | 168.50 | NA | BQL | |
| | | | | 1 H | 08DEC2020 | 09:12 | 169.00 | 353 | BQL | |
| | | | | 2 H | 08DEC2020 | 10:12 | 170.00 | 237 | BQL | |
| | | | | 4 H | 08DEC2020 | 12:12 | 172.00 | 183 | BQL | |
| | | | | 6 H | 08DEC2020 | 14:12 | 174.00 | 180 | BQL | |
| | | | | 8 H | 08DEC2020 | 16:12 | 176.00 | 162 | BQL | |
| | | | DAY 11 | 72 H | 11DEC2020 | 08:12 | 240.00 | 342 | NA | |
| | | | DAY 15 | 168 H | 15DEC2020 | 08:12 | 336.00 | 343 | NA | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
 Individual Values: All Enrolled Subjects
 Treatment Arm 1: TA + LOR

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|-------|------------|-----------|-------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1038 | F/43 | TA | DAY 1 | PRE-DOSE | 01DEC2020 | 08:14 | -0.17 | <20.0 | NA | |
| | | | | 1 H | 01DEC2020 | 09:24 | 1.00 | 502 | NA | |
| | | | | 2 H | 01DEC2020 | 10:24 | 2.00 | 972 | NA | |
| | | | | 4 H | 01DEC2020 | 12:24 | 4.00 | 3050 | NA | |
| | | | | 6 H | 01DEC2020 | 14:24 | 6.00 | 3700 | NA | |
| | | | | 8 H | 01DEC2020 | 16:24 | 8.00 | 4260 | NA | |
| | | | | 10 H | 01DEC2020 | 18:24 | 10.00 | 3580 | NA | |
| | | | | 12 H | 01DEC2020 | 20:24 | 12.00 | 3240 | NA | |
| | | | | 24 H | 02DEC2020 | 08:24 | 24.00 | 1480 | NA | |
| | | | | 48 H | 03DEC2020 | 08:24 | 48.00 | 887 | NA | |
| | | | | 96 H | 05DEC2020 | 08:24 | 96.00 | 341 | NA | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
Individual Values: All Enrolled Subjects
Treatment Arm 1: TA + LOR

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|--------|------------|-----------|-------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1038 | F/43 | LOR | DAY 8 | PRE-DOSE | 08DEC2020 | 08:19 | 167.92 | 676 | BQL | |
| | | | | 0.25 H | 08DEC2020 | 08:39 | 168.25 | NA | BQL | |
| | | | | 0.5 H | 08DEC2020 | 08:54 | 168.50 | NA | BQL | |
| | | | | 1 H | 08DEC2020 | 09:24 | 169.00 | 455 | BQL | |
| | | | | 2 H | 08DEC2020 | 10:24 | 170.00 | 378 | BQL | |
| | | | | 4 H | 08DEC2020 | 12:24 | 172.00 | 325 | BQL | |
| | | | | 6 H | 08DEC2020 | 14:24 | 174.00 | 310 | BQL | |
| | | | | 8 H | 08DEC2020 | 16:24 | 176.00 | 372 | BQL | |
| | | | DAY 11 | 72 H | 11DEC2020 | 08:24 | 240.00 | 402 | NA | |
| | | | DAY 15 | 168 H | 15DEC2020 | 08:24 | 336.00 | 322 | NA | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
 Individual Values: All Enrolled Subjects
 Treatment Arm 1: TA + LOR

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|-------|------------|-----------|-------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1040 | F/44 | TA | DAY 1 | PRE-DOSE | 01DEC2020 | 08:26 | -0.17 | <20.0 | NA | |
| | | | | 1 H | 01DEC2020 | 09:36 | 1.00 | 2240 | NA | |
| | | | | 2 H | 01DEC2020 | 10:36 | 2.00 | 5540 | NA | |
| | | | | 4 H | 01DEC2020 | 12:36 | 4.00 | 10800 | NA | |
| | | | | 6 H | 01DEC2020 | 14:36 | 6.00 | 9160 | NA | |
| | | | | 8 H | 01DEC2020 | 16:36 | 8.00 | 11600 | NA | |
| | | | | 10 H | 01DEC2020 | 18:36 | 10.00 | 7310 | NA | |
| | | | | 12 H | 01DEC2020 | 20:36 | 12.00 | 8930 | NA | |
| | | | | 24 H | 02DEC2020 | 08:36 | 24.00 | 6950 | NA | |
| | | | | 48 H | 03DEC2020 | 08:36 | 48.00 | 2200 | NA | |
| | | | | 96 H | 05DEC2020 | 08:36 | 96.00 | 341 | NA | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
 Individual Values: All Enrolled Subjects
 Treatment Arm 1: TA + LOR

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments | |
|------------|----------|-----------------|-------|------------|-----------|-----------|------------------------------|------------|-------------|----------------------------------|--|
| | | | | | Date | Time | | | | | |
| 1040 | F/44 | LOR | DAY 8 | PRE-DOSE | 08DEC2020 | 08:31 | 167.92 | 822 | BQL | | |
| | | | | 0.25 H | 08DEC2020 | 08:51 | 168.25 | NA | BQL | | |
| | | | | 0.5 H | 08DEC2020 | 09:06 | 168.50 | NA | BQL | | |
| | | | | 1 H | 08DEC2020 | 09:36 | 169.00 | 423 | BQL | | |
| | | | | 2 H | 08DEC2020 | 10:36 | 170.00 | 360 | BQL | | |
| | | | | 4 H | 08DEC2020 | 12:36 | 172.00 | 304 | BQL | | |
| | | | | 6 H | 08DEC2020 | 14:36 | 174.00 | 296 | BQL | | |
| | | | | 8 H | 08DEC2020 | 16:36 | 176.00 | 268 | BQL | | |
| | | | | DAY 11 | 72 H | 11DEC2020 | 08:36 | 240.00 | 270 | NA | |
| | | | | DAY 15 | 168 H | 15DEC2020 | 08:36 | 336.00 | 204 | NA | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
 Individual Values: All Enrolled Subjects
 Treatment Arm 2: LOR + TA

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|----------|------------|-----------|-------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1001 | M/39 | LOR | DAY 1 | PRE-DOSE | 21OCT2020 | 09:40 | | NA | BQL | |
| | | | | 0.25 H | 21OCT2020 | 10:00 | | NA | BQL | |
| | | | | 0.5 H | 21OCT2020 | 10:15 | | NA | BQL | |
| | | | | 1 H | 21OCT2020 | 10:45 | | NA | BQL | |
| | | | | 2 H | 21OCT2020 | 11:45 | | NA | BQL | |
| | | | | 4 H | 21OCT2020 | 13:45 | | NA | BQL | |
| | | | | 6 H | 21OCT2020 | 15:45 | | NA | BQL | |
| | TA | DAY 8 | PRE-DOSE | 28OCT2020 | 09:40 | -0.08 | <20.0 | NA | | |
| | | | 1 H | 28OCT2020 | 10:45 | 1.00 | 499 | BQL | | |
| | | | 2 H | 28OCT2020 | 11:45 | 2.00 | 561 | BQL | | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).
 Key: TA=triamcinolone acetone, LOR=lorecivivint
 NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit
 Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
Individual Values: All Enrolled Subjects
Treatment Arm 2: LOR + TA

| Subject ID | Sex/ Age | Study Injection | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|------------|--------|-----------------|------------------------------|------------|-------------|----------------------------------|
| | | | | Date | Time | | | | |
| 1001 | M/39 | TA | DAY 8 | 4 H | 28OCT2020 13:45 | 4.00 | 577 | BQL | |
| | | | | 6 H | 28OCT2020 15:45 | 6.00 | 544 | NA | |
| | | | | 8 H | 28OCT2020 17:45 | 8.00 | 497 | BQL | |
| | | | | 10 H | 28OCT2020 19:45 | 10.00 | 445 | NA | |
| | | | | 12 H | 28OCT2020 21:45 | 12.00 | 440 | NA | |
| | | | | DAY 9 | 24 H | 29OCT2020 09:45 | 24.00 | 709 | BQL |
| | | | DAY 10 | 48 H | 30OCT2020 09:45 | 48.00 | 708 | BQL | |
| | | | DAY 12 | 96 H | 01NOV2020 09:45 | 96.00 | 480 | BQL | |
| | | | DAY 15 | 168 H | 04NOV2020 09:45 | 168.00 | 385 | NA | |
| | | | DAY 18 | 240 H | 07NOV2020 09:45 | 240.00 | 330 | NA | |
| | | | DAY 22 | 336 H | 11NOV2020 09:45 | 336.00 | 426 | NA | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetate, LOR=lorazepam

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit
Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
 Individual Values: All Enrolled Subjects
 Treatment Arm 2: LOR + TA

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|----------|------------|-----------|-------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1002 | M/44 | LOR | DAY 1 | PRE-DOSE | 21OCT2020 | 09:55 | | NA | BQL | |
| | | | | 0.25 H | 21OCT2020 | 10:15 | | NA | BQL | |
| | | | | 0.5 H | 21OCT2020 | 10:30 | | NA | BQL | |
| | | | | 1 H | 21OCT2020 | 11:00 | | NA | BQL | |
| | | | | 2 H | 21OCT2020 | 12:00 | | NA | BQL | |
| | | | | 4 H | 21OCT2020 | 14:00 | | NA | BQL | |
| | | | | 6 H | 21OCT2020 | 16:00 | | NA | BQL | |
| | TA | DAY 8 | PRE-DOSE | 28OCT2020 | 09:55 | -0.08 | <20.0 | NA | | |
| | | | 1 H | 28OCT2020 | 11:00 | 1.00 | 13100 | BQL | | |
| | | | 2 H | 28OCT2020 | 12:00 | 2.00 | 16200 | BQL | | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetonide, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
 Individual Values: All Enrolled Subjects
 Treatment Arm 2: LOR + TA

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|--------|------------|-----------|-----------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1002 | M/44 | TA | DAY 8 | 4 H | 28OCT2020 | 14:00 | 4.00 | 20400 | BQL | |
| | | | | 6 H | 28OCT2020 | 16:00 | 6.00 | 13600 | NA | |
| | | | | 8 H | 28OCT2020 | 18:00 | 8.00 | 12800 | BQL | |
| | | | | 10 H | 28OCT2020 | 20:00 | 10.00 | 9550 | NA | |
| | | | | 12 H | 28OCT2020 | 22:00 | 12.00 | 7400 | NA | |
| | | | | DAY 9 | 24 H | 29OCT2020 | 10:00 | 24.00 | 9670 | BQL |
| | | | DAY 10 | 48 H | 30OCT2020 | 10:00 | 48.00 | 6520 | BQL | |
| | | | DAY 12 | 96 H | 01NOV2020 | 10:00 | 96.00 | 824 | BQL | |
| | | | DAY 15 | 168 H | 04NOV2020 | 10:00 | 168.00 | 139 | NA | |
| | | | DAY 18 | 240 H | 07NOV2020 | 10:00 | 240.00 | 36.7 | NA | |
| | | | DAY 22 | 336 H | 11NOV2020 | 10:00 | 336.00 | <20.0 | NA | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetate, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
 Individual Values: All Enrolled Subjects
 Treatment Arm 2: LOR + TA

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|----------|------------|-----------|-------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1005 | M/38 | LOR | DAY 1 | PRE-DOSE | 21OCT2020 | 10:10 | | NA | BQL | |
| | | | | 0.25 H | 21OCT2020 | 10:30 | | NA | BQL | |
| | | | | 0.5 H | 21OCT2020 | 10:45 | | NA | BQL | |
| | | | | 1 H | 21OCT2020 | 11:15 | | NA | BQL | |
| | | | | 2 H | 21OCT2020 | 12:15 | | NA | BQL | |
| | | | | 4 H | 21OCT2020 | 14:15 | | NA | BQL | |
| | | | | 6 H | 21OCT2020 | 16:15 | | NA | BQL | |
| | TA | DAY 8 | PRE-DOSE | 28OCT2020 | 10:10 | -0.08 | <20.0 | NA | | |
| | | | 1 H | 28OCT2020 | 11:15 | 1.00 | 5590 | BQL | | |
| | | | 2 H | 28OCT2020 | 12:15 | 2.00 | 16300 | BQL | | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
 Individual Values: All Enrolled Subjects
 Treatment Arm 2: LOR + TA

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|--------|------------|-----------|-----------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1005 | M/38 | TA | DAY 8 | 4 H | 28OCT2020 | 14:15 | 4.00 | 30200 | BQL | |
| | | | | 6 H | 28OCT2020 | 16:15 | 6.00 | 31500 | NA | |
| | | | | 8 H | 28OCT2020 | 18:15 | 8.00 | 26300 | BQL | |
| | | | | 10 H | 28OCT2020 | 20:15 | 10.00 | 29200 | NA | |
| | | | | 12 H | 28OCT2020 | 22:15 | 12.00 | 27000 | NA | |
| | | | | DAY 9 | 24 H | 29OCT2020 | 10:15 | 24.00 | 19300 | BQL |
| | | | DAY 10 | 48 H | 30OCT2020 | 10:15 | 48.00 | 7510 | BQL | |
| | | | DAY 12 | 96 H | 01NOV2020 | 10:15 | 96.00 | 1610 | BQL | |
| | | | DAY 15 | 168 H | 04NOV2020 | 10:15 | 168.00 | 435 | NA | |
| | | | DAY 18 | 240 H | 07NOV2020 | 10:15 | 240.00 | 149 | NA | |
| | | | DAY 22 | 336 H | 11NOV2020 | 10:15 | 336.00 | 29.7 | NA | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetonide, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
 Individual Values: All Enrolled Subjects
 Treatment Arm 2: LOR + TA

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|----------|------------|-----------|-------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1007 | F/27 | LOR | DAY 1 | PRE-DOSE | 21OCT2020 | 09:25 | | NA | BQL | |
| | | | | 0.25 H | 21OCT2020 | 09:45 | | NA | BQL | |
| | | | | 0.5 H | 21OCT2020 | 10:00 | | NA | BQL | |
| | | | | 1 H | 21OCT2020 | 10:30 | | NA | BQL | |
| | | | | 2 H | 21OCT2020 | 11:30 | | NA | BQL | |
| | | | | 4 H | 21OCT2020 | 13:30 | | NA | BQL | |
| | | | | 6 H | 21OCT2020 | 15:30 | | NA | BQL | |
| | TA | DAY 8 | PRE-DOSE | 28OCT2020 | 09:25 | -0.08 | <20.0 | NA | | |
| | | | 1 H | 28OCT2020 | 10:30 | 1.00 | 2290 | BQL | | |
| | | | 2 H | 28OCT2020 | 11:30 | 2.00 | 2540 | BQL | | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
 Individual Values: All Enrolled Subjects
 Treatment Arm 2: LOR + TA

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|--------|------------|-----------|-------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1007 | F/27 | TA | DAY 8 | 4 H | 28OCT2020 | 13:30 | 4.00 | 2330 | BQL | |
| | | | | 6 H | 28OCT2020 | 15:30 | 6.00 | 1930 | NA | |
| | | | | 8 H | 28OCT2020 | 17:30 | 8.00 | 2570 | BQL | |
| | | | | 10 H | 28OCT2020 | 19:30 | 10.00 | 2520 | NA | |
| | | | | 12 H | 28OCT2020 | 21:31 | 12.02 | 1810 | NA | |
| | | | DAY 9 | 24 H | 29OCT2020 | 09:30 | 24.00 | 1540 | BQL | |
| | | | DAY 10 | 48 H | 30OCT2020 | 09:30 | 48.00 | 1000 | BQL | |
| | | | DAY 12 | 96 H | 01NOV2020 | 09:30 | 96.00 | 588 | BQL | |
| | | | DAY 15 | 168 H | 04NOV2020 | 09:30 | 168.00 | 574 | NA | |
| | | | DAY 18 | 240 H | 07NOV2020 | 09:37 | 240.12 | 544 | NA | |
| | | | DAY 22 | 336 H | 11NOV2020 | 09:30 | 336.00 | 407 | NA | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetate, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit
 Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
 Individual Values: All Enrolled Subjects
 Treatment Arm 2: LOR + TA

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|----------|------------|-----------|-------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1011 | M/32 | LOR | DAY 1 | PRE-DOSE | 05NOV2020 | 09:31 | | NA | BQL | |
| | | | | 0.25 H | 05NOV2020 | 09:51 | | NA | BQL | |
| | | | | 0.5 H | 05NOV2020 | 10:06 | | NA | BQL | |
| | | | | 1 H | 05NOV2020 | 10:36 | | NA | BQL | |
| | | | | 2 H | 05NOV2020 | 11:36 | | NA | BQL | |
| | | | | 4 H | 05NOV2020 | 13:36 | | NA | BQL | |
| | | | | 6 H | 05NOV2020 | 15:36 | | NA | BQL | |
| | TA | DAY 8 | PRE-DOSE | 12NOV2020 | 09:26 | -0.17 | <20.0 | NA | | |
| | | | 1 H | 12NOV2020 | 10:36 | 1.00 | 2360 | BQL | | |
| | | | 2 H | 12NOV2020 | 11:36 | 2.00 | 1970 | BQL | | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
Individual Values: All Enrolled Subjects
Treatment Arm 2: LOR + TA

| Subject ID | Sex/ Age | Study Injection | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|------------|--------|-----------------|------------------------------|------------|-------------|----------------------------------|
| | | | | Date | Time | | | | |
| 1011 | M/32 | TA | DAY 8 | 4 H | 12NOV2020 13:36 | 4.00 | 1320 | BQL | |
| | | | | 6 H | 12NOV2020 15:36 | 6.00 | 883 | NA | |
| | | | | 8 H | 12NOV2020 17:36 | 8.00 | 884 | BQL | |
| | | | | 10 H | 12NOV2020 19:36 | 10.00 | 747 | NA | |
| | | | | 12 H | 12NOV2020 21:36 | 12.00 | 764 | NA | |
| | | | DAY 9 | 24 H | 13NOV2020 09:36 | 24.00 | 620 | BQL | |
| | | | DAY 10 | 48 H | 14NOV2020 09:36 | 48.00 | 453 | BQL | |
| | | | DAY 12 | 96 H | 16NOV2020 09:36 | 96.00 | 367 | BQL | |
| | | | DAY 15 | 168 H | 19NOV2020 09:36 | 168.00 | 307 | NA | |
| | | | DAY 18 | 240 H | 22NOV2020 09:36 | 240.00 | 421 | NA | |
| | | | DAY 22 | 336 H | 26NOV2020 09:36 | 336.00 | 216 | NA | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetate, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
 Individual Values: All Enrolled Subjects
 Treatment Arm 2: LOR + TA

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|-----------|------------|-----------|-------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1012 | M/37 | LOR | DAY 1 | PRE-DOSE | 05NOV2020 | 09:43 | | NA | BQL | |
| | | | | 0.25 H | 05NOV2020 | 10:03 | | NA | BQL | |
| | | | | 0.5 H | 05NOV2020 | 10:18 | | NA | BQL | |
| | | | | 1 H | 05NOV2020 | 10:48 | | NA | BQL | |
| | | | | 2 H | 05NOV2020 | 11:48 | | NA | BQL | |
| | | | | 4 H | 05NOV2020 | 13:48 | | NA | BQL | |
| | | | | 6 H | 05NOV2020 | 15:48 | | NA | BQL | |
| | | | | 8 H | 05NOV2020 | 17:49 | | NA | BQL | |
| | | TA | DAY 8 | PRE-DOSE | 12NOV2020 | 09:38 | -0.17 | <20.0 | NA | |
| | | | | 1 H | 12NOV2020 | 10:48 | 1.00 | 208 | BQL | |
| | | 2 H | 12NOV2020 | 11:48 | 2.00 | 240 | BQL | | | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
 Individual Values: All Enrolled Subjects
 Treatment Arm 2: LOR + TA

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|--------|------------|-----------|-------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1012 | M/37 | TA | DAY 8 | 4 H | 12NOV2020 | 13:48 | 4.00 | 343 | BQL | |
| | | | | 6 H | 12NOV2020 | 15:48 | 6.00 | 373 | NA | |
| | | | | 8 H | 12NOV2020 | 17:48 | 8.00 | 673 | BQL | |
| | | | | 10 H | 12NOV2020 | 19:48 | 10.00 | 728 | NA | |
| | | | | 12 H | 12NOV2020 | 21:48 | 12.00 | 782 | NA | |
| | | | DAY 9 | 24 H | 13NOV2020 | 09:48 | 24.00 | 816 | BQL | |
| | | | DAY 10 | 48 H | 14NOV2020 | 09:48 | 48.00 | 580 | BQL | |
| | | | DAY 12 | 96 H | 16NOV2020 | 09:48 | 96.00 | 398 | BQL | |
| | | | DAY 15 | 168 H | 19NOV2020 | 09:48 | 168.00 | 292 | NA | |
| | | | DAY 18 | 240 H | 22NOV2020 | 09:48 | 240.00 | 409 | NA | |
| | | | DAY 22 | 336 H | 26NOV2020 | 09:48 | 336.00 | 253 | NA | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetate, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
 Individual Values: All Enrolled Subjects
 Treatment Arm 2: LOR + TA

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|-------|------------|-----------|-------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1013 | M/45 | LOR | DAY 1 | PRE-DOSE | 05NOV2020 | 09:55 | | NA | BQL | |
| | | | | 0.25 H | 05NOV2020 | 10:15 | | NA | BQL | |
| | | | | 0.5 H | 05NOV2020 | 10:30 | | NA | BQL | |
| | | | | 1 H | 05NOV2020 | 11:00 | | NA | BQL | |
| | | | | 2 H | 05NOV2020 | 12:00 | | NA | BQL | |
| | | | | 4 H | 05NOV2020 | 14:00 | | NA | BQL | |
| | | | | 6 H | 05NOV2020 | 16:00 | | NA | BQL | |
| | | | | 8 H | 05NOV2020 | 18:00 | | NA | BQL | |
| | | TA | DAY 8 | PRE-DOSE | 12NOV2020 | 09:50 | -0.17 | <20.0 | NA | |
| | 1 H | | | 12NOV2020 | 11:00 | 1.00 | 657 | BQL | | |
| | 2 H | | | 12NOV2020 | 12:00 | 2.00 | 1280 | BQL | | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
Individual Values: All Enrolled Subjects
Treatment Arm 2: LOR + TA

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|--------|------------|-----------|-------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1013 | M/45 | TA | DAY 8 | 4 H | 12NOV2020 | 14:00 | 4.00 | 1860 | BQL | |
| | | | | 6 H | 12NOV2020 | 16:00 | 6.00 | 1760 | NA | |
| | | | | 8 H | 12NOV2020 | 18:00 | 8.00 | 1840 | BQL | |
| | | | | 10 H | 12NOV2020 | 20:00 | 10.00 | 1690 | NA | |
| | | | | 12 H | 12NOV2020 | 22:00 | 12.00 | 1630 | NA | |
| | | | DAY 9 | 24 H | 13NOV2020 | 10:00 | 24.00 | 1540 | BQL | |
| | | | DAY 10 | 48 H | 14NOV2020 | 10:00 | 48.00 | 639 | BQL | |
| | | | DAY 12 | 96 H | 16NOV2020 | 10:00 | 96.00 | 588 | BQL | |
| | | | DAY 15 | 168 H | 19NOV2020 | 10:00 | 168.00 | 472 | NA | |
| | | | DAY 18 | 240 H | 22NOV2020 | 10:00 | 240.00 | 454 | NA | |
| | | | DAY 22 | 336 H | 26NOV2020 | 10:00 | 336.00 | 505 | NA | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetate, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
 Individual Values: All Enrolled Subjects
 Treatment Arm 2: LOR + TA

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|----------|------------|-----------|-------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1016 | M/48 | LOR | DAY 1 | PRE-DOSE | 05NOV2020 | 10:07 | | NA | BQL | |
| | | | | 0.25 H | 05NOV2020 | 10:27 | | NA | BQL | |
| | | | | 0.5 H | 05NOV2020 | 10:42 | | NA | BQL | |
| | | | | 1 H | 05NOV2020 | 11:12 | | NA | BQL | |
| | | | | 2 H | 05NOV2020 | 12:12 | | NA | BQL | |
| | | | | 4 H | 05NOV2020 | 14:12 | | NA | BQL | |
| | | | | 6 H | 05NOV2020 | 16:12 | | NA | BQL | |
| | TA | DAY 8 | PRE-DOSE | 12NOV2020 | 10:02 | -0.17 | <20.0 | NA | | |
| | | | 1 H | 12NOV2020 | 11:12 | 1.00 | 540 | BQL | | |
| | | | 2 H | 12NOV2020 | 12:12 | 2.00 | 618 | BQL | | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
 Individual Values: All Enrolled Subjects
 Treatment Arm 2: LOR + TA

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|--------|------------|-----------|-------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1016 | M/48 | TA | DAY 8 | 4 H | 12NOV2020 | 14:12 | 4.00 | 729 | BQL | |
| | | | | 6 H | 12NOV2020 | 16:12 | 6.00 | 660 | NA | |
| | | | | 8 H | 12NOV2020 | 18:12 | 8.00 | 700 | BQL | |
| | | | | 10 H | 12NOV2020 | 20:12 | 10.00 | 759 | NA | |
| | | | | 12 H | 12NOV2020 | 22:12 | 12.00 | 804 | NA | |
| | | | DAY 9 | 24 H | 13NOV2020 | 10:12 | 24.00 | 1130 | BQL | |
| | | | DAY 10 | 48 H | 14NOV2020 | 10:12 | 48.00 | 783 | BQL | |
| | | | DAY 12 | 96 H | 16NOV2020 | 10:12 | 96.00 | 512 | BQL | |
| | | | DAY 15 | 168 H | 19NOV2020 | 10:12 | 168.00 | 423 | NA | |
| | | | DAY 18 | 240 H | 22NOV2020 | 10:12 | 240.00 | 384 | NA | |
| | | | DAY 22 | 336 H | 26NOV2020 | 10:12 | 336.00 | 458 | NA | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
 Individual Values: All Enrolled Subjects
 Treatment Arm 2: LOR + TA

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|----------|------------|-----------|-------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1019 | F/51 | LOR | DAY 1 | PRE-DOSE | 05NOV2020 | 08:57 | | NA | BQL | |
| | | | | 0.25 H | 05NOV2020 | 09:15 | | NA | BQL | |
| | | | | 0.5 H | 05NOV2020 | 09:30 | | NA | BQL | |
| | | | | 1 H | 05NOV2020 | 10:00 | | NA | BQL | |
| | | | | 2 H | 05NOV2020 | 11:00 | | NA | BQL | |
| | | | | 4 H | 05NOV2020 | 13:00 | | NA | BQL | |
| | | | | 6 H | 05NOV2020 | 15:02 | | NA | BQL | |
| | 8 H | 05NOV2020 | 17:00 | | NA | BQL | | | | |
| | TA | DAY 8 | PRE-DOSE | 12NOV2020 | 08:50 | -0.17 | <20.0 | NA | | |
| | | | 1 H | 12NOV2020 | 10:00 | 1.00 | 388 | BQL | | |
| | | | 2 H | 12NOV2020 | 11:00 | 2.00 | 428 | BQL | | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
 Individual Values: All Enrolled Subjects
 Treatment Arm 2: LOR + TA

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|--------|------------|-----------|-------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1019 | F/51 | TA | DAY 8 | 4 H | 12NOV2020 | 13:00 | 4.00 | 717 | BQL | |
| | | | | 6 H | 12NOV2020 | 15:00 | 6.00 | 755 | NA | |
| | | | | 8 H | 12NOV2020 | 17:00 | 8.00 | 906 | BQL | |
| | | | | 10 H | 12NOV2020 | 19:00 | 10.00 | 900 | NA | |
| | | | | 12 H | 12NOV2020 | 21:00 | 12.00 | 747 | NA | |
| | | | DAY 9 | 24 H | 13NOV2020 | 09:00 | 24.00 | 905 | BQL | |
| | | | DAY 10 | 48 H | 14NOV2020 | 09:00 | 48.00 | 714 | BQL | |
| | | | DAY 12 | 96 H | 16NOV2020 | 09:00 | 96.00 | 396 | BQL | |
| | | | DAY 15 | 168 H | 19NOV2020 | 09:00 | 168.00 | 341 | NA | |
| | | | DAY 18 | 240 H | 22NOV2020 | 09:00 | 240.00 | 406 | NA | |
| | | | DAY 22 | 336 H | 26NOV2020 | 09:00 | 336.00 | 698 | NA | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
 Individual Values: All Enrolled Subjects
 Treatment Arm 2: LOR + TA

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|----------|------------|-----------|-------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1021 | F/47 | LOR | DAY 1 | PRE-DOSE | 05NOV2020 | 09:19 | | NA | BQL | |
| | | | | 0.25 H | 05NOV2020 | 09:39 | | NA | BQL | |
| | | | | 0.5 H | 05NOV2020 | 09:54 | | NA | BQL | |
| | | | | 1 H | 05NOV2020 | 10:24 | | NA | BQL | |
| | | | | 2 H | 05NOV2020 | 11:24 | | NA | BQL | |
| | | | | 4 H | 05NOV2020 | 13:24 | | NA | BQL | |
| | | | | 6 H | 05NOV2020 | 15:24 | | NA | BQL | |
| | TA | DAY 8 | PRE-DOSE | 12NOV2020 | 09:14 | -0.17 | <20.0 | NA | | |
| | | | 1 H | 12NOV2020 | 10:24 | 1.00 | 635 | BQL | | |
| | | | 2 H | 12NOV2020 | 11:24 | 2.00 | 1220 | BQL | | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
Individual Values: All Enrolled Subjects
Treatment Arm 2: LOR + TA

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|--------|------------|-----------|-----------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1021 | F/47 | TA | DAY 8 | 4 H | 12NOV2020 | 13:24 | 4.00 | 1750 | BQL | |
| | | | | 6 H | 12NOV2020 | 15:24 | 6.00 | 1230 | NA | |
| | | | | 8 H | 12NOV2020 | 17:24 | 8.00 | 1050 | BQL | |
| | | | | 10 H | 12NOV2020 | 19:24 | 10.00 | 794 | NA | |
| | | | | 12 H | 12NOV2020 | 21:24 | 12.00 | 751 | NA | |
| | | | | DAY 9 | 24 H | 13NOV2020 | 09:24 | 24.00 | 784 | BQL |
| | | | DAY 10 | 48 H | 14NOV2020 | 09:24 | 48.00 | 550 | BQL | |
| | | | DAY 12 | 96 H | 16NOV2020 | 09:24 | 96.00 | 409 | BQL | |
| | | | DAY 15 | 168 H | 19NOV2020 | 09:24 | 168.00 | 312 | NA | |
| | | | DAY 18 | 240 H | 22NOV2020 | 09:24 | 240.00 | 246 | NA | |
| | | | DAY 22 | 336 H | 26NOV2020 | 09:24 | 336.00 | 202 | NA | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetate, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
 Individual Values: All Enrolled Subjects
 Treatment Arm 2: LOR + TA

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|-------|------------|-----------|-------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1024 | M/47 | LOR | DAY 1 | PRE-DOSE | 18NOV2020 | 09:31 | | NA | BQL | |
| | | | | 0.25 H | 18NOV2020 | 09:51 | | NA | BQL | |
| | | | | 0.5 H | 18NOV2020 | 10:06 | | NA | BQL | |
| | | | | 1 H | 18NOV2020 | 10:36 | | NA | BQL | |
| | | | | 2 H | 18NOV2020 | 11:36 | | NA | BQL | |
| | | | | 4 H | 18NOV2020 | 13:36 | | NA | BQL | |
| | | | | 6 H | 18NOV2020 | 15:36 | | NA | BQL | |
| | | | | 8 H | 18NOV2020 | 17:36 | | NA | BQL | |
| | | TA | DAY 8 | PRE-DOSE | 25NOV2020 | 09:26 | -0.17 | <20.0 | NA | |
| | | | | 1 H | 25NOV2020 | 10:36 | 1.00 | 8320 | BQL | |
| | | | | 2 H | 25NOV2020 | 11:36 | 2.00 | 12400 | BQL | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
Individual Values: All Enrolled Subjects
Treatment Arm 2: LOR + TA

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|--------|------------|-----------|-----------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1024 | M/47 | TA | DAY 8 | 4 H | 25NOV2020 | 13:36 | 4.00 | 14100 | BQL | |
| | | | | 6 H | 25NOV2020 | 15:36 | 6.00 | 13900 | NA | |
| | | | | 8 H | 25NOV2020 | 17:36 | 8.00 | 15300 | BQL | |
| | | | | 10 H | 25NOV2020 | 19:36 | 10.00 | 14200 | NA | |
| | | | | 12 H | 25NOV2020 | 21:36 | 12.00 | 12000 | NA | |
| | | | | DAY 9 | 24 H | 26NOV2020 | 09:36 | 24.00 | 9250 | BQL |
| | | | DAY 10 | 48 H | 27NOV2020 | 09:36 | 48.00 | 2070 | BQL | |
| | | | DAY 12 | 96 H | 29NOV2020 | 09:36 | 96.00 | 371 | BQL | |
| | | | DAY 15 | 168 H | 02DEC2020 | 09:36 | 168.00 | 267 | NA | |
| | | | DAY 18 | 240 H | 05DEC2020 | 09:36 | 240.00 | 238 | NA | |
| | | | DAY 22 | 336 H | 09DEC2020 | 09:36 | 336.00 | 259 | NA | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetonide, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
 Individual Values: All Enrolled Subjects
 Treatment Arm 2: LOR + TA

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|----------|------------|-----------|-------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1025 | F/39 | LOR | DAY 1 | PRE-DOSE | 18NOV2020 | 08:55 | | NA | BQL | |
| | | | | 0.25 H | 18NOV2020 | 09:15 | | NA | BQL | |
| | | | | 0.5 H | 18NOV2020 | 09:30 | | NA | BQL | |
| | | | | 1 H | 18NOV2020 | 10:00 | | NA | BQL | |
| | | | | 2 H | 18NOV2020 | 11:00 | | NA | BQL | |
| | | | | 4 H | 18NOV2020 | 13:00 | | NA | BQL | |
| | | | | 6 H | 18NOV2020 | 15:00 | | NA | BQL | |
| | TA | DAY 8 | PRE-DOSE | 25NOV2020 | 08:50 | -0.17 | <20.0 | NA | | |
| | | | 1 H | 25NOV2020 | 10:00 | 1.00 | 1850 | BQL | | |
| | | | 2 H | 25NOV2020 | 11:00 | 2.00 | 2460 | BQL | | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
 Individual Values: All Enrolled Subjects
 Treatment Arm 2: LOR + TA

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|--------|------------|-----------|-----------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1025 | F/39 | TA | DAY 8 | 4 H | 25NOV2020 | 13:00 | 4.00 | 3760 | BQL | |
| | | | | 6 H | 25NOV2020 | 15:00 | 6.00 | 3370 | NA | |
| | | | | 8 H | 25NOV2020 | 17:00 | 8.00 | 3270 | BQL | |
| | | | | 10 H | 25NOV2020 | 19:00 | 10.00 | 2670 | NA | |
| | | | | 12 H | 25NOV2020 | 21:00 | 12.00 | 2040 | NA | |
| | | | | DAY 9 | 24 H | 26NOV2020 | 09:00 | 24.00 | 1120 | BQL |
| | | | DAY 10 | 48 H | 27NOV2020 | 09:00 | 48.00 | 646 | BQL | |
| | | | DAY 12 | 96 H | 29NOV2020 | 09:00 | 96.00 | 347 | BQL | |
| | | | DAY 15 | 168 H | 02DEC2020 | 09:00 | 168.00 | 237 | NA | |
| | | | DAY 18 | 240 H | 05DEC2020 | 09:00 | 240.00 | 305 | NA | |
| | | | DAY 22 | 336 H | 09DEC2020 | 09:00 | 336.00 | 271 | NA | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
 Individual Values: All Enrolled Subjects
 Treatment Arm 2: LOR + TA

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|-------|------------|-----------|-------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1028 | F/53 | LOR | DAY 1 | PRE-DOSE | 18NOV2020 | 09:07 | | NA | BQL | |
| | | | | 0.25 H | 18NOV2020 | 09:27 | | NA | BQL | |
| | | | | 0.5 H | 18NOV2020 | 09:42 | | NA | BQL | |
| | | | | 1 H | 18NOV2020 | 10:12 | | NA | BQL | |
| | | | | 2 H | 18NOV2020 | 11:12 | | NA | BQL | |
| | | | | 4 H | 18NOV2020 | 13:12 | | NA | BQL | |
| | | | | 6 H | 18NOV2020 | 15:12 | | NA | BQL | |
| | | | | 8 H | 18NOV2020 | 17:12 | | NA | BQL | |
| | | TA | DAY 8 | PRE-DOSE | 25NOV2020 | 09:02 | -0.17 | <20.0 | NA | |
| | | | | 1 H | 25NOV2020 | 10:12 | 1.00 | 10500 | BQL | |
| | | | | 2 H | 25NOV2020 | 11:12 | 2.00 | 20800 | BQL | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
Individual Values: All Enrolled Subjects
Treatment Arm 2: LOR + TA

| Subject ID | Sex/ Age | Study Injection | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|------------|--------|-----------------|------------------------------|------------|-------------|----------------------------------|
| | | | | Date | Time | | | | |
| 1028 | F/53 | TA | DAY 8 | 4 H | 25NOV2020 13:12 | 4.00 | 29800 | BQL | |
| | | | | 6 H | 25NOV2020 15:12 | 6.00 | 34300 | NA | |
| | | | | 8 H | 25NOV2020 17:12 | 8.00 | 31100 | BQL | |
| | | | | 10 H | 25NOV2020 19:12 | 10.00 | 29300 | NA | |
| | | | | 12 H | 25NOV2020 21:12 | 12.00 | 24200 | NA | |
| | | | | DAY 9 | 24 H | 26NOV2020 09:12 | 24.00 | 18800 | BQL |
| | | | DAY 10 | 48 H | 27NOV2020 09:12 | 48.00 | 8940 | BQL | |
| | | | DAY 12 | 96 H | 29NOV2020 09:12 | 96.00 | 2290 | BQL | |
| | | | DAY 15 | 168 H | 02DEC2020 09:12 | 168.00 | 656 | NA | |
| | | | DAY 18 | 240 H | 05DEC2020 09:12 | 240.00 | 245 | NA | |
| | | | DAY 22 | 336 H | 09DEC2020 09:12 | 336.00 | 21.9 | NA | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetate, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
 Individual Values: All Enrolled Subjects
 Treatment Arm 2: LOR + TA

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|-----------|------------|-----------|-------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1029 | M/42 | LOR | DAY 1 | PRE-DOSE | 18NOV2020 | 09:43 | | NA | BQL | |
| | | | | 0.25 H | 18NOV2020 | 10:03 | | NA | BQL | |
| | | | | 0.5 H | 18NOV2020 | 10:18 | | NA | BQL | |
| | | | | 1 H | 18NOV2020 | 10:48 | | NA | BQL | |
| | | | | 2 H | 18NOV2020 | 11:48 | | NA | BQL | |
| | | | | 4 H | 18NOV2020 | 13:48 | | NA | BQL | |
| | | | | 6 H | 18NOV2020 | 15:48 | | NA | BQL | |
| | | | | 8 H | 18NOV2020 | 17:48 | | NA | BQL | |
| | | TA | DAY 8 | PRE-DOSE | 25NOV2020 | 09:38 | -0.17 | <20.0 | NA | |
| | | | | 1 H | 25NOV2020 | 10:48 | 1.00 | 255 | BQL | |
| | | 2 H | 25NOV2020 | 11:48 | 2.00 | 210 | BQL | | | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
 Individual Values: All Enrolled Subjects
 Treatment Arm 2: LOR + TA

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|--------|------------|-----------|-----------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1029 | M/42 | TA | DAY 8 | 4 H | 25NOV2020 | 13:48 | 4.00 | 241 | BQL | |
| | | | | 6 H | 25NOV2020 | 15:48 | 6.00 | 194 | NA | |
| | | | | 8 H | 25NOV2020 | 17:48 | 8.00 | 271 | BQL | |
| | | | | 10 H | 25NOV2020 | 19:48 | 10.00 | 245 | NA | |
| | | | | 12 H | 25NOV2020 | 21:48 | 12.00 | 243 | NA | |
| | | | | DAY 9 | 24 H | 26NOV2020 | 09:48 | 24.00 | 454 | BQL |
| | | | DAY 10 | 48 H | 27NOV2020 | 09:48 | 48.00 | 409 | BQL | |
| | | | DAY 12 | 96 H | 29NOV2020 | 09:48 | 96.00 | 273 | BQL | |
| | | | DAY 15 | 168 H | 02DEC2020 | 09:48 | 168.00 | 160 | NA | |
| | | | DAY 18 | 240 H | 05DEC2020 | 09:48 | 240.00 | 298 | NA | |
| | | | DAY 22 | 336 H | 09DEC2020 | 09:48 | 336.00 | 198 | NA | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetate, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
 Individual Values: All Enrolled Subjects
 Treatment Arm 2: LOR + TA

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|-------|------------|-----------|-------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1030 | M/23 | LOR | DAY 1 | PRE-DOSE | 18NOV2020 | 09:55 | | NA | BQL | |
| | | | | 0.25 H | 18NOV2020 | 10:15 | | NA | BQL | |
| | | | | 0.5 H | 18NOV2020 | 10:30 | | NA | BQL | |
| | | | | 1 H | 18NOV2020 | 11:00 | | NA | BQL | |
| | | | | 2 H | 18NOV2020 | 12:00 | | NA | BQL | |
| | | | | 4 H | 18NOV2020 | 14:00 | | NA | BQL | |
| | | | | 6 H | 18NOV2020 | 16:00 | | NA | BQL | |
| | | | | 8 H | 18NOV2020 | 18:00 | | NA | BQL | |
| | | TA | DAY 8 | PRE-DOSE | 25NOV2020 | 09:50 | -0.17 | <20.0 | NA | |
| | | | | 1 H | 25NOV2020 | 11:00 | 1.00 | 186 | BQL | |
| | | | | 2 H | 25NOV2020 | 12:00 | 2.00 | 178 | BQL | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
 Individual Values: All Enrolled Subjects
 Treatment Arm 2: LOR + TA

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|--------|------------|-----------|-----------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1030 | M/23 | TA | DAY 8 | 4 H | 25NOV2020 | 14:00 | 4.00 | 298 | BQL | |
| | | | | 6 H | 25NOV2020 | 16:00 | 6.00 | 211 | NA | |
| | | | | 8 H | 25NOV2020 | 18:00 | 8.00 | 86.2 | BQL | |
| | | | | 10 H | 25NOV2020 | 20:00 | 10.00 | 136 | NA | |
| | | | | 12 H | 25NOV2020 | 22:00 | 12.00 | 224 | NA | |
| | | | | DAY 9 | 24 H | 26NOV2020 | 10:00 | 24.00 | 568 | BQL |
| | | | DAY 10 | 48 H | 27NOV2020 | 10:00 | 48.00 | 575 | BQL | |
| | | | DAY 12 | 96 H | 29NOV2020 | 10:00 | 96.00 | 328 | BQL | |
| | | | DAY 15 | 168 H | 02DEC2020 | 10:00 | 168.00 | 397 | NA | |
| | | | DAY 18 | 240 H | 05DEC2020 | 10:00 | 240.00 | 230 | NA | |
| | | | DAY 22 | 336 H | 09DEC2020 | 10:00 | 336.00 | 257 | NA | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
 Individual Values: All Enrolled Subjects
 Treatment Arm 2: LOR + TA

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|----------|------------|-----------|-------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1034 | M/38 | LOR | DAY 1 | PRE-DOSE | 01DEC2020 | 09:07 | | NA | BQL | |
| | | | | 0.25 H | 01DEC2020 | 09:27 | | NA | BQL | |
| | | | | 0.5 H | 01DEC2020 | 09:42 | | NA | BQL | |
| | | | | 1 H | 01DEC2020 | 10:12 | | NA | BQL | |
| | | | | 2 H | 01DEC2020 | 11:12 | | NA | BQL | |
| | | | | 4 H | 01DEC2020 | 13:12 | | NA | BQL | |
| | | | | 6 H | 01DEC2020 | 15:12 | | NA | BQL | |
| | TA | DAY 8 | PRE-DOSE | 08DEC2020 | 09:02 | -0.17 | <20.0 | NA | | |
| | | | 1 H | 08DEC2020 | 10:12 | 1.00 | 8720 | BQL | | |
| | | | 2 H | 08DEC2020 | 11:12 | 2.00 | 13300 | BQL | | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
Individual Values: All Enrolled Subjects
Treatment Arm 2: LOR + TA

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|--------|------------|-----------|-----------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1034 | M/38 | TA | DAY 8 | 4 H | 08DEC2020 | 13:12 | 4.00 | 18900 | BQL | |
| | | | | 6 H | 08DEC2020 | 15:12 | 6.00 | 20000 | NA | |
| | | | | 8 H | 08DEC2020 | 17:12 | 8.00 | 20800 | BQL | |
| | | | | 10 H | 08DEC2020 | 19:12 | 10.00 | 17900 | NA | |
| | | | | 12 H | 08DEC2020 | 21:12 | 12.00 | 14600 | NA | |
| | | | | DAY 9 | 24 H | 09DEC2020 | 09:12 | 24.00 | 12800 | BQL |
| | | | DAY 10 | 48 H | 10DEC2020 | 09:12 | 48.00 | 6400 | BQL | |
| | | | DAY 12 | 96 H | 12DEC2020 | 09:12 | 96.00 | 1310 | BQL | |
| | | | DAY 15 | 168 H | 15DEC2020 | 09:12 | 168.00 | 112 | NA | |
| | | | DAY 18 | 240 H | 18DEC2020 | 09:12 | 240.00 | <20.0 | NA | |
| | | | DAY 22 | 336 H | 22DEC2020 | 09:12 | 336.00 | <20.0 | NA | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
 Individual Values: All Enrolled Subjects
 Treatment Arm 2: LOR + TA

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|----------|------------|-----------|-------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1035 | M/39 | LOR | DAY 1 | PRE-DOSE | 01DEC2020 | 09:19 | | NA | BQL | |
| | | | | 0.25 H | 01DEC2020 | 09:39 | | NA | BQL | |
| | | | | 0.5 H | 01DEC2020 | 09:54 | | NA | BQL | |
| | | | | 1 H | 01DEC2020 | 10:24 | | NA | BQL | |
| | | | | 2 H | 01DEC2020 | 11:24 | | NA | BQL | |
| | | | | 4 H | 01DEC2020 | 13:24 | | NA | BQL | |
| | | | | 6 H | 01DEC2020 | 15:24 | | NA | BQL | |
| | | | | 8 H | 01DEC2020 | 17:24 | | NA | BQL | |
| | TA | DAY 8 | PRE-DOSE | 08DEC2020 | 09:14 | -0.17 | <20.0 | NA | | |
| | | | 1 H | 08DEC2020 | 10:24 | 1.00 | 24100 | BQL | | |
| | | | 2 H | 08DEC2020 | 11:24 | 2.00 | 33900 | BQL | | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit
 Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
Individual Values: All Enrolled Subjects
Treatment Arm 2: LOR + TA

| Subject ID | Sex/ Age | Study Injection | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|------------|--------|-----------------|------------------------------|------------|-------------|----------------------------------|
| | | | | Date | Time | | | | |
| 1035 | M/39 | TA | DAY 8 | 4 H | 08DEC2020 13:24 | 4.00 | 40200 | BQL | |
| | | | | 6 H | 08DEC2020 15:24 | 6.00 | 38400 | NA | |
| | | | | 8 H | 08DEC2020 17:24 | 8.00 | 33000 | BQL | |
| | | | | 10 H | 08DEC2020 19:24 | 10.00 | 26300 | NA | |
| | | | | 12 H | 08DEC2020 21:24 | 12.00 | 24000 | NA | |
| | | | | 24 H | 09DEC2020 09:24 | 24.00 | 12500 | BQL | |
| | | | DAY 9 | 48 H | 10DEC2020 09:24 | 48.00 | 3140 | BQL | |
| | | | DAY 10 | 96 H | 12DEC2020 09:24 | 96.00 | 668 | BQL | |
| | | | DAY 12 | 168 H | 15DEC2020 09:24 | 168.00 | 63.0 | NA | |
| | | | DAY 15 | 240 H | 18DEC2020 09:24 | 240.00 | <20.0 | NA | |
| | | | DAY 18 | 336 H | 22DEC2020 09:24 | 336.00 | <20.0 | NA | |
| | | | DAY 22 | | | | | | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetonide, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
 Individual Values: All Enrolled Subjects
 Treatment Arm 2: LOR + TA

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|----------|------------|-----------|-------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1037 | F/35 | LOR | DAY 1 | PRE-DOSE | 01DEC2020 | 08:43 | | NA | BQL | |
| | | | | 0.25 H | 01DEC2020 | 09:03 | | NA | BQL | |
| | | | | 0.5 H | 01DEC2020 | 09:18 | | NA | BQL | |
| | | | | 1 H | 01DEC2020 | 09:48 | | NA | BQL | |
| | | | | 2 H | 01DEC2020 | 10:48 | | NA | BQL | |
| | | | | 4 H | 01DEC2020 | 12:48 | | NA | BQL | |
| | | | | 6 H | 01DEC2020 | 14:48 | | NA | BQL | |
| | TA | DAY 8 | PRE-DOSE | 08DEC2020 | 08:38 | -0.17 | <20.0 | NA | | |
| | | | 1 H | 08DEC2020 | 09:48 | 1.00 | 456 | BQL | | |
| | | | 2 H | 08DEC2020 | 10:48 | 2.00 | 688 | BQL | | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
 Individual Values: All Enrolled Subjects
 Treatment Arm 2: LOR + TA

| Subject ID | Sex/ Age | Study Injection | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|------------|--------|-----------|------------------------------|------------|-------------|----------------------------------|
| | | | | Date | Time | | | | |
| 1037 | F/35 | TA | DAY 8 | 4 H | 08DEC2020 | 12:48 | 4.00 | 667 | BQL |
| | | | | 6 H | 08DEC2020 | 14:48 | 6.00 | 845 | NA |
| | | | | 8 H | 08DEC2020 | 16:48 | 8.00 | 868 | BQL |
| | | | | 10 H | 08DEC2020 | 18:48 | 10.00 | 668 | NA |
| | | | | 12 H | 08DEC2020 | 20:48 | 12.00 | 717 | NA |
| | | | DAY 9 | 24 H | 09DEC2020 | 08:48 | 24.00 | 785 | BQL |
| | | | DAY 10 | 48 H | 10DEC2020 | 08:48 | 48.00 | 790 | BQL |
| | | | DAY 12 | 96 H | 12DEC2020 | 08:48 | 96.00 | 568 | BQL |
| | | | DAY 15 | 168 H | 15DEC2020 | 08:48 | 168.00 | 455 | NA |
| | | | DAY 18 | 240 H | 18DEC2020 | 08:48 | 240.00 | 478 | NA |
| | | | DAY 22 | 336 H | 22DEC2020 | 08:48 | 336.00 | 489 | NA |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetonide, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
 Individual Values: All Enrolled Subjects
 Treatment Arm 2: LOR + TA

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|----------|------------|-----------|-------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1039 | F/45 | LOR | DAY 1 | PRE-DOSE | 01DEC2020 | 08:55 | | NA | BQL | |
| | | | | 0.25 H | 01DEC2020 | 09:15 | | NA | BQL | |
| | | | | 0.5 H | 01DEC2020 | 09:30 | | NA | BQL | |
| | | | | 1 H | 01DEC2020 | 10:00 | | NA | BQL | |
| | | | | 2 H | 01DEC2020 | 11:00 | | NA | BQL | |
| | | | | 4 H | 01DEC2020 | 13:00 | | NA | BQL | |
| | | | | 6 H | 01DEC2020 | 15:00 | | NA | BQL | |
| | TA | DAY 8 | PRE-DOSE | 08DEC2020 | 08:50 | -0.17 | <20.0 | NA | | |
| | | | 1 H | 08DEC2020 | 10:00 | 1.00 | 583 | BQL | | |
| | | | 2 H | 08DEC2020 | 11:00 | 2.00 | 637 | BQL | | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
Individual Values: All Enrolled Subjects
Treatment Arm 2: LOR + TA

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|--------|------------|-----------|-------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 1039 | F/45 | TA | DAY 8 | 4 H | 08DEC2020 | 13:00 | 4.00 | 1080 | BQL | |
| | | | | 6 H | 08DEC2020 | 15:00 | 6.00 | 1180 | NA | |
| | | | | 8 H | 08DEC2020 | 17:00 | 8.00 | 1220 | BQL | |
| | | | | 10 H | 08DEC2020 | 19:00 | 10.00 | 1040 | NA | |
| | | | | 12 H | 08DEC2020 | 21:00 | 12.00 | 984 | NA | |
| | | | DAY 9 | 24 H | 09DEC2020 | 09:00 | 24.00 | 1130 | BQL | |
| | | | DAY 10 | 48 H | 10DEC2020 | 09:00 | 48.00 | 753 | BQL | |
| | | | DAY 12 | 96 H | 12DEC2020 | 09:00 | 96.00 | 495 | BQL | |
| | | | DAY 15 | 168 H | 15DEC2020 | 09:00 | 168.00 | 401 | NA | |
| | | | DAY 18 | 240 H | 18DEC2020 | 09:00 | 240.00 | 373 | NA | |
| | | | DAY 22 | 336 H | 22DEC2020 | 09:00 | 336.00 | 276 | NA | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
 Individual Values: All Enrolled Subjects
 Treatment Arm 2: LOR + TA

| Subject ID | Sex/ Age | Study Injection | Day | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|----------|------------|-----------|-------|------------------------------|------------|-------------|----------------------------------|
| | | | | | Date | Time | | | | |
| 9020 | M/46 | LOR | DAY 1 | PRE-DOSE | 18NOV2020 | 09:19 | | NA | BQL | |
| | | | | 0.25 H | 18NOV2020 | 09:39 | | NA | BQL | |
| | | | | 0.5 H | 18NOV2020 | 09:54 | | NA | BQL | |
| | | | | 1 H | 18NOV2020 | 10:24 | | NA | BQL | |
| | | | | 2 H | 18NOV2020 | 11:24 | | NA | BQL | |
| | | | | 4 H | 18NOV2020 | 13:24 | | NA | BQL | |
| | | | | 6 H | 18NOV2020 | 15:24 | | NA | BQL | |
| | 8 H | 18NOV2020 | 17:24 | | NA | BQL | | | | |
| | TA | DAY 8 | PRE-DOSE | 25NOV2020 | 09:14 | -0.17 | <20.0 | NA | | |
| | | | 1 H | 25NOV2020 | 10:24 | 1.00 | 6610 | BQL | | |
| | | | 2 H | 25NOV2020 | 11:24 | 2.00 | 12900 | BQL | | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)

DATA LISTING 16.2.5.2

Blood Sample Collection Details for Pharmacokinetic Analysis and Plasma Pharmacokinetic Concentration
Individual Values: All Enrolled Subjects
Treatment Arm 2: LOR + TA

| Subject ID | Sex/ Age | Study Injection | Time point | Sample | | Actual Time from TA Dose (h) | TA (pg/mL) | LOR (ng/mL) | TA and LOR Any Relevant Comments |
|------------|----------|-----------------|------------|--------|-----------------|------------------------------|------------|-------------|----------------------------------|
| | | | | Date | Time | | | | |
| 9020 | M/46 | TA | DAY 8 | 4 H | 25NOV2020 13:24 | 4.00 | 23200 | BQL | |
| | | | | 6 H | 25NOV2020 15:24 | 6.00 | 21000 | NA | |
| | | | | 8 H | 25NOV2020 17:24 | 8.00 | 19900 | BQL | |
| | | | | 10 H | 25NOV2020 19:24 | 10.00 | 18800 | NA | |
| | | | | 12 H | 25NOV2020 21:24 | 12.00 | 17500 | NA | |
| | | | | 24 H | 26NOV2020 09:24 | 24.00 | 11300 | BQL | |
| | | | DAY 9 | 48 H | 27NOV2020 09:24 | 48.00 | 3240 | BQL | |
| | | | DAY 10 | 96 H | 29NOV2020 09:24 | 96.00 | 671 | BQL | |
| | | | DAY 12 | 168 H | 02DEC2020 09:24 | 168.00 | 307 | NA | |
| | | | DAY 15 | 240 H | 05DEC2020 09:24 | 240.00 | 307 | NA | |
| | | | DAY 18 | 336 H | 09DEC2020 09:24 | 336.00 | 293 | NA | |
| | | | DAY 22 | | | | | | |

Note: All subjects were to receive both study injections, TA and LOR, in a randomized manner in either Treatment Arm 1 (TA then LOR) or Treatment Arm 2 (LOR then TA).

Key: TA=triamcinolone acetone, LOR=lorecivivint

NC = Not Calculated, NA = Not Applicable, BQL = Below Quantification Limit

Lower Limit of Quantification (LLOQ): 0.100 ng/mL (LOR), 20.0 pg/mL (TA)